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INTRODUCTION 
The siddha system represents the antiquity of ancient medicinal tradition prevalent 
in the Indian sub-continent. The immortal siddha masters describe „health‟ as the 
harmonious equilibrium in the three main functionalities in the human body. 
-the balanced functioning of the three Thodams in the body  
-the function of the seven thathus or tissues that constitute the formation of the body; 
and the resultant of their functions  
-the balanced functioning of the elimination system; the malam 
Man is nothing but a world in miniature containing the five elements and all the 
various principles mentioned in siddha system. 
Siddha system of medicine is a science which gives ailments to body and mind. Life 
style advocacies, selection of functional foods and person oriented treatment regimen are 
the uniqueness of Siddha system of medicine. 
Siddhars are the one who attained perfection in yogic practices to ultimately reach 
the stage of immortality. Through higher- level yogic practices they attained a state of ultra-
luminosity that results in invisibility; thus they remained impervious to ordinary vision. 
Such Siddhars worked incessantly for the propagation of knowledge and the evolution of 
souls. 
 
According to Siddha system of Medicine, diseases are classified into 4448 in 
number. Yugi classified 20 types of Pramegam into 3 categories. Four types under vatham, 
six under pitham ten under kabam. Madhumegam comes under pitham category. 
 
Madhumegam is also called as "Neerizhivu" characterised by increased and   
frequent passing of urine, which is sweet in odour, resulting in gradual diminution of 
udalthathukkal . 
 
The clinical features of madhumegam can be correlated with type 2diabetes mellitus 
in modern science. 
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The term “Diabetes mellitus” is a clinical syndrome characterised by an increase in 
plasma blood glucose. Diabetes has many causes but is commonly due to type 1 and type 
2diabetes. Type 1 diabetes is caused by autoimmune destruction of insulin producing cells 
in the pancreas, resulting in absolute insulin deficiency, whereas type 2 diabetes is 
characterised by resistance to the action of insulin and an inability to produce sufficient 
insulin to overcome this insulin resistance. 
 
The first WHO Global report on diabetes demonstrates that the number of adults 
living with diabetes has almost quadrupled since 1980 to 422 million adults. This dramatic 
rise is largely due to the rise in type 2 diabetes and factors driving it include overweight and 
obesity. In 2012 alone diabetes caused 1.5 million deaths. 
According to statistics from the International Diabetes Federation (IDF), India has 
more diabetics than any other nation of the world. Current estimates peg the number of 
diabetics in the country at about 62 million – an increase of over 10 million from 2011 
when estimates suggested that about 50.8 million people in the country were suffering from 
the disease. By the year 2030, over 100 million people in India are likely to suffer from 
diabetes. 
 
Yogam is a precious art contributed to the siddha system of medicine. Yogam is one 
of the kayalkalpam methods that preserve physical and mental health problems.The 
qualitative well-being is something that yoga and other Indian systems of medicine have 
considered important for thousands of years.Yogam has become the 13th intangible cultural 
heritage that has been listed from India so far with UNESCO. The Indian government is 
capitalizing on yoga‟s popularity by supporting global events such as the International Day 
of Yoga that make the practice even more susceptible to global and commercial forces. 
Thus it is gaining awareness and importance among the people. 
 
Nowadays sedentary life style of the people have lead many metabolic disorders and 
one among such disease with a large epidemiology is “Madhumegam”.So I have chosen to 
conduct my study on Yogam in the management of Madhumegam along with the trial drug 
Marutham pattai kudineer. The In-vitro &In-vivo studies of most of the ingredients like 
Syzygium cumini, Strychnos potatorum, Triphala, Terminalia arjunashows potent anti-
diabetic activity. 
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The currently available oral anti-hyperglycaemic agents for clinical use have 
characteristic profile of side effects, drug dependency and drug resistance in other systems. 
The management of Diabetes with agents devoid of any side effects is still a challenge to 
the health care sector.Hence, in recent times there has been an intense search for drugless 
measures not only to control DM, but also to prevent its complications .Therefore a cost 
effective and an integrated management is the need of the hour.Yoga practice has a 
behavioural activation component which enhances and also preserves physical fitness, 
coordination and flexibility, while preventing or minimizing deterioration. Hence, yoga has 
special significance in the case of progressive metabolic disorders such as Diabetes. 
 
The author is obliged to conduct this study to provide a holistic approach through 
yogam based life style changes in diabetic patients. 
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Aim: 
To evaluate the effectiveness of Yogam Therapyand Marutham Pattai Kudineer for 
the management of “Madhumegam “(Type II Diabetes Mellitus)  
 
Primary Objective: 
To study the effectiveness of yogam in the management of Madhumegam(Type II 
Diabetes Mellitus) . 
 
Secondary objective : 
 
 To examine the Siddha diagnostic methods such as Envagaithervu, Neerkkuri and 
Neikkuri in Madhumegam patients 
 To evaluate the safety of the trial drugs by doing toxicological studies acute and 
chronic in animal models. 
 Biochemical analysis of drug. 
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MADHUMEGAM 
 
Siddha system of medicine is an ancient system and it deals not only with the body 
of man but also with the inner soul. The word Siddha comes from Siddhi which means an 
object to be attained. It generally refers to the Astama Siddhi i.e. the eight super natural 
powers.  
Both Nature and Human body is made up of five elements (Piruthivi, Appu, 
Theayu,Vaayu & Agaayam) .Any adverse changes in the universe causes the same effect in 
man because  what exists in universe exists in man also.  
 
In Siddha system of medicine, diseases are classified into 4448 types.  According to 
Yugi vaithiya chinthaamani, Meghanoi is classified into 20 types. “Madhumegam” is one 
among them, which comes under Pitha (Azhal) type.  
 
Definition – Madhumegam: 
 
Madhumegam is a clinical condition characterized by frequent passage of urine 
more than the normal resulting in deterioration and diminution of seven thathus (Saram, 
senner, oon, kozhuppu, enbu, moolai, and sukkilam). 
 
 mz;ikah abf; fbf;F ePupwq;F 
  Kbf;fbf;F miu ehop jdpNy fhZk; 
ntz;ikahd dbdjdpw;whd; gpbf;Fk; 
  kpf;fhd rlk; ntSj;J Nkdp fz;Zk; 
       -A+fp itj;jpa rp;e;jhkzp.  
rupahf Nkfj;jh yghd thA 
  jhd;Giff;F NkNywpf; fghyr; #lhk; 
Ngupjhd Nkfj;jh yj;jp nte;J 
  Nghkg;gh jirnte;J uj;jk; tw;wpg; 
gupthfpj; jrthathy; ke;jq; nfhz;L 
  ngUe;jPdp kyge;jk; cjhd thA 
tupthf Njfnkyhk; tpl ePuhNy 
  nka;aope;j Nkfnkd;w jpUg jhr;Nr. 
rpj;jh; ehb E}y; 
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Synonyms of Madhumegam;  
 According to Siddha Maruthuvam, the synonyms of Madhumegam are “Inippuneer” 
and “Neerizhivu.”  
 
Etiology:  
 The authentic etiological factors described by various siddhars are as follows:  
Nfhijau; fytp NghijnfhOj;jkP dpiwr;rp Nghijg; 
ghJtha; nea;Ak; ghYk; gupTl Dz;g uhfpy; 
Nrhjghz; LUt kpf;f Rf;fpy gpuNk fe;jhd; 
XJeP upopT Nru Tz;nld twpe;J nfhs;Ns. 
-mfj;jpau; 1200 
 
The above poem quotes that excessive intake of Ghee, Milk, Fish, toddy and 
excessive indulgence in sex leads to Madhumegam, Excessive body heat (Azhal) and 
excessive hunger also leads to Madhumegam.  
 
Pshycosomatic factors:  
  
Yugimunivar and other siddhars stress a great importance to Pshycosomatic factor. 
All antisocial activities ultimately result in subjective guiltiness and pshycosomatic stress 
resulting in diseases like Diabetes, Peptic ulcer and Hypertension. 
  
,ak;gNt MWFzk; gpd;dQ; nra;jy; 
  Mak;Nt Myaj;jpw; ryk;tpl; Nlhu;f;F 
Mjpahk;Ntjj;ij j;J}~pw; Njhu;f;Fk; 
  RUf;fhf Nkfk;te; Jw;g tpf;Fe; jhNd 
     A+fp itj;jpa rpe;jhkzp. 
Noi Enn (Classification):  
  
Twenty varieties of Megha disorders have been discussed by Yugimuni, Agathiyar 
and Threaiyar.  
 
Yugimuni classified Megha disorder into 20 types. Among this Vatha 4, Pitta 6 and 
Kabha 10types.  
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 In Siddha text like Thirumoolar vaidiyam 600,Prameham is also called as 
Neerizhivu. In Agasthiyar texts and “Yugimuni Vaidiya Chinthamani 800”, Madhumegam is 
one among the 20 varieties of Prameham. Each author who have dealt megha disorders 
have differently classified them under three thosam and have given names according to their 
concept. But the number, signs and symptoms of the classified disorders are almost 
identical in the description of the disease.  
 
Classification:  
 
1) Classification of Prameham according toYugimuni Vaidiya chinthamani 800 as 
follows:  
 
Types under vatha:  
1. Nei mana neer  
2. Pasu mana neer 
3. Oon mana neer 
4. Seel mana neer 
Types under Pitta  
1. Yanai kozhuppu mana neer 
2. Katralai mana neer  
3. Chunna mana neer 
4. Inippu megam 
5. Palingu neer 
6. Muyarkuruthi neer 
Types under kabha 
1. Vasa neer 
2. Theli neer 
3. Moolai urukku neer 
4. Ilaneer neer 
5. Kal neer 
6. Sukkila neer 
7. Thean neer 
8. Uppu neer 
9. Kalu neer 
10. Iraichi neer 
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Noi kuri kunangal (Clinical features):  
 
Yugimuni has described the signs and symptoms of Madhumegam are passing of 
urine in large quantity at regular intervals, while passing urine the patient experiences 
burning and spasmodic pain in the urethra and dull pain in the testis.  
 
The urine thus passed is cold, slimy to touch, has brownish yellow in colour 
produces white sediments which adhere to the bottom of the vessel in which it is collected. 
The skin is pale and there is generalized tenderness. If it is not diagnosed in time and not 
initiated proper treatment with diet restriction, the disease will run a fulminating course 
resulting in death within five years of periods.  
 
Avaithaigal (Complications of Madhumegam):  
 
fhzNt Kjytj;ijr; ruPue; jhDq; 
  fdkhf gUj;jpWfp ePu;j;J thuk; 
NtzNt Ntz;lhf;fp afyk; gz;Z 
  kpf;ftpuz; lhktj;ij tpsk;g Nfsha; 
%zNt %j;jpug;gP ilAkhr; Rf;y 
  KfKOfpj; Nj[Rjhd; kpfNt Fd;Wk; 
ehzNt %d;whF ktj;ijf; Fj;jhd; 
  ehtwSk; thAtJ kPWe; jhNd 
 
jhwhd ehytj;ij aq;f jhFQ; 
  rd;dpaJ ghjKz;lh ike;j tj;ijj; 
Njwhd ePu;g; ngUFe; jhJ e~;lk; 
  epiyahS ktj;ijAlw; fpilnfhs; shJ 
Kdhd Ku;r;irtU Nko tj;ij 
  kpf;ftNuh rfQ;Rthre; Njf rhl;bak; 
Vdhd vl;lht jtj;ij jhNd 
  vOfpuj;jp gpsit Ae;jhd; kpfTz; lhNk 
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cz;lhF nkhd;gjh ktj;ij Nfsha; 
xOf;fhd thrhuq; fpUkp Az;lhk; 
gz;lhd gj;jhe;j dtj;ijf; Nfsha; 
  ghukhk; raq;fz;L guj;jpf; NfFk; 
ntz;lhF Nkfe;jh dpUg Jf;Fk; 
  tpsf;fpaNjhu; jrtj;ij tptuQ; nrhd;Ndhk;. 
Siddhar Yugimuni has described the complications of Madhumegam as “Avaithaigal”. 
There are ten avaithaigal described one by one as follows:  
 
1. Obesity and dilation of urethral orifice  
2. Body becomes dry and loses its lustre .Urinary disorders. 
3. Dryness of the tongue and distension of the abdomen due flatulence. 
4. Delirium (Toxic condition) supervenes following dehydration due to excessive 
elimination of tissue fluid.  
5. Restlessness due to loss of vital fluid in urine    
6. Unconsciousness and restlessness.  
7. Nausea, tastelessness, dyspnoea, exhaustion.  
8. Carbuncle and multiple abscess formation  
9. Maggot formation and generalized emaciation.  
10. Cough with profuse expectoration leading to death.  
 
Mukkutra Verupaadugal (Pathology of Madhumegam):  
The whole ancient medicine is based upon the „Thridosham theory‟. Due to intrinsic 
and extrinsic factors, the pitha(Azhal) in the body gets altered. This is followed by the 
derangement of metabolic energy caused by the involvement of vatha(Vali). Finally, the 
function of vatha(Vali) and kabam(Iyam) also altered resulting in dearrangement of normal 
structure and functions of the seven thathus.  
 
Udal Kattugal:  
                   These are seven basic principles which constitute the entire body. There are 
seven Udal kattugal described in Siddha text. 
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SEVEN PHYSICAL CONSTITUENTS OF THE BODY  
 
1. Saaram      - This gives mental and physical perseverance.  
2. Senneer      - Imparts colour to the body and nourishes the body  
3. Oon            - It gives shape to the body according to the physical activity 
   and covers the bone. 
4. Kozhuppu   - It lubricates the joints and other parts of the body for   
smooth functioning.   
5. Enbu          - Supports the frame and responsible for the postures and   
movements of the body.  
6. Moolai       - It occupies the medulla of the bones and gives strength and   
softness to them.  
7. Sukkilam  - It is responsible for reproduction 
 
VARIATIONS OF THE PHYSICAL CONSTITUENTS 
 
UDAL 
THATHUKKAAL 
INCREASED FEATURES DECREASED FEATURES 
SARAM 
Leads to a disease identical to the 
increase in kabam like loss of 
appetite,indigestion etc.. 
Dryness of skin, tiredness, 
diminished activity of sense 
organs, loss of weight, lassitude  
SENNEER 
 Boils in different parts of the 
body, jaundice, haematuria, colic 
pain,anorexia 
Pallor of the body, Tiredness, 
lassitude, cold, anaemia 
OON 
Hypermuscular around the neck, 
cheeks, vernical ulcer tumour in 
abdomen, thigh and genitalia. 
Impairment of sense organs, 
joints, jaws, thigh and genitalia 
gets shortened. 
KOZHUPPU 
Identical feature of increased oon, 
associated with  dyspnoea on 
exertion, 
 Pain in the hip region, 
spleenomegaly and emaciation. 
ENBU Growth of bones and teeth. 
Bone diseases, loosening of teeth 
and nails, splitting and falling of 
hair. 
MOOLAI 
Heaviness of the body and eyes, 
swollen inter phalangeal joints, 
oliguria and non-healing ulcers. 
Osteoporosis &Blurred vision. 
SUKKILAM (OR) 
SURONITHAM 
Increased sexual activity, urinary 
calculi. 
Pain in the genitalia, failure to 
reproduction 
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In case of Madhumegam, all seven thathus are affected.  
1. Saram  -  Tiredness  
2. Senneer -  Reduced strength  
3. Oon  -  Weight loss  
4. Kozhupppu -  Weight loss or Obese  
5. Enbu  -  Joint pain  
6. Moolai  -  Bone Marrow Affected  
7. Sukkilam -  Body becomes dry and loses its lusture    
 
Piniyari muraimai:  
  Piniyari muraimai is the method of diagnosing the disease affecting the people. It is 
based upon the following aspects:  
 
1. Poriyalarithal  
2. Pulanaalarithal  
3. Vinaathal  
4. Envagaithervugal  
5. Naadiparitchai  
 
The above principles correspond to the methodology of inspection, palpation and 
interrogation of modern medicine.  
 
Poriyalarithal and Pulanalarithal: 
 
 Iympori is considered as the five sense organs namely Nose, Tongue, Eye, Skin and 
Ear.While Iympulan is considered as the five sense of perception. They are smell, Taste, 
Vision, touch and sound. Physician‟s pori and pulan are used as the tools for examining the 
pori, pulan of the patient.   
 
Envagai thervugal:  
 
Eight different kinds of tests to be applied or attended by a physician before arriving 
a correct diagnosis. These are also called Attavitha Paritchai or Attasthanna Parikshai.  
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 Envagai thervugal is considered as physician‟s Instrument. There are, 
1. Naadi (Pulse)  
2. Sparisam (Palpation)  
3. Naa (Tongue examination)  
4. Niram (Colour of the body)  
5. Mozhi (Speech)  
6. Vizhi (Eye Examination)  
7. Malam (Motion Examination)  
8. Moothiram (Urine examination)  
 
Therefore, to arrive at the diagnosis for any disease, it is imperative to apply the 
Envagai thervugal.  
“njhFf;fYw;W ml;ltpj ghPl;ir jd;id 
      FYf;fKyWk; gz;bhNu njspthfg; 
gFf;fwpa ehbia eP gpbj;jg; ghU 
 gfh;fpd;w thh;j;ijia ghh; ehitg; ghU 
tFf;fwpa Njfkij njhl;Lg;ghU 
 tskhd rhPuj;jpd; epwf;ijg; ghU  
rfpf;fhpa kyj;ijg;ghh; ryj;ijg; ghu 
 rhh;e;j tpop jidg;ghh;j;J njsptha;f; fhNd” 
mfj;jpah; ty;yhjp 600 
1. Naadi (Pulse):  
  Naadi is the vital force.Any change in the three doshas are best diagnosed by 
feeling the naadi. Naadi is an important observation for diagnosis and prognosis.Naadi  is 
responsible for the existence of life and can be felt one inch below the wrist on the radial 
side by means of palapation with the tips of index, middle and ring finger corresponding to 
Vatham ,Ptham and Kabam. 
 
2. Sparisam: (Palpation):  
 The following points are elicited by Sparisam , the temperature of skin (Heat or 
cold) , smoothness, roughness, softness, sweat , dryness , sensation .   
3. Naa: 
Colour, coating, ulcer, deviation, roughness, silky soft & any abnormality of the 
tongue,     
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4. Niram: 
 Colour of skin, palm etc. 
 
5. Mozhi: 
 Mode & quality of Speech,  
 
6. Vizhi: 
 Colour, vision,dryness, itching, cataract and any abnormality 
 
7. Malam Faeces):  
 In the examination of Malam, Niram (colour ) ,Nurai (froth), Erugal (Solid).,Elagal 
(Semisolid or liquid), quantity (increased or decreased) smell can be noted other 
examination like diarrhea, presence of blood, mucus, undigested matter in the stools and 
odour can also be studied.  
 
8. Moothiram:  (Urine)  
 In the examinantion of urine, colour, odour, quantity of urine, the presence of froth, 
deposits,blood, pus, inorganic sediments, abnormal constituents such as sugar, protein etc… 
and the frequency of micturitions are to be noted.  
The diagnosis is usually arrived at by methods of urine examinations called  
i. Neerkuri  
ii. Neikuru  
 
i)Neerkuri  
In Neerkuri, Niram, Edai, Manam, Nurai and Enjal of the urine voided is noted. This 
has been already mentioned in Envagai thervugal.  
 
 The following parameters in the urine should be examined.  
Niram  : It indicates the colour of the urine voided.  
Edai   : It indicates the specific gravity of urine (increased or 
  decreased quantity)          
Manam : It indicates the smell of urine voided.  
Nurai   : It indicates the frothy nature of urine voided  
Enjal   : It indicates the quantity of urine  
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Neerkuri of Madhumegam is studied as follows:  
 
Niram  : Clear and white.This is due to kabha vitiation and it is not amenable 
to treatment. 
Edai  : Urine is thick  
Manam : Smells like honey.  
Nurai   : It is frothy at the time of urination.  
Enjal  : Large quantity of urine is passed. This will result in the loss of large  
volume of water and life sustaining minerals resulting in Fatigue, 
exhaustion and weakness.   
Neikuri:  
  
A drop of Gingelly oil is dropped into a wide mouthed vessel containing the urine to 
be tested and kept it under the sunlight in a air free place. The variations of the three thathus 
in disease can be diagnosed by the behaviour of Gingelly oil on the surface of urine.   
 
The drop of oil lengthening like a snake indicates Vatham (Vali)   
The drop of oil spreading like a ring it indicates Pitham (Azhal)     
If the oil drops assumes a pearl shape it is presumed to be Kabham(Iyam). 
By the careful examination of the urine with gingelly oil, the physicians can know 
whether the disease is curable or not. For this purpose Siddhars have explained various 
spreading tendencies of oil on urine surface to define the prognosis of the disease.  
 
Maruthuvam (treatment)  
itj;jpar; nray; itj;jpahkhNk 
gythW khWjyile;J nfLf;fpd;w cliy epiyf;Fk;gb 
khWjy; mZfhkYk; xNu jd;ikahf 
nra;Jk; mjdhyhQ; nrapyf; Fiwtpd;wp 
elf;fr; nra;tJ njJNth mJNt itj;jpak; 
       -jpU%yu;800 
 Siddha system of medicine besides treating the diseases and improves the body 
condition. This is said as follows:  
a.Neekkam (Treatment)  
b. Niraivu (Restoration)  
c.Kaappu (Prevention 
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Neekkam  (Treatment)  
 The three uyir thathus which are responsible for organization, regularization and 
integration of the bodily structures and their physiological functions are always kept in a 
state of equilibrium by word, thought, deed and food of the individual. The general 
aetiological factors for constitutional discomfort is said to be incompatible diet, mental and 
physical activities.  
  
So, it is essential to know the disease and the cause for the onset of the disease, 
before treating the patient.  The nature of the patient, the severity of illness, the season and 
time of the occurrence of the diseases must be observed 
 
Niraivu (Restoration)  
 Patients‟ needs good discussion, motivation and persuasion to accept the eventuality 
of Diabetes and prepare for a lifestyle that provides optimization of metabolic status. 
Suitable and effective medicinal preparations have to be administered in the beginning itself 
to neutralize and eliminate the damage in the body tissues.  
 
 Siddhars aimed at bringing the three thosam in equilibrium in the treatment of 
disease. The treatment regimen has been constituted from plant to metal and mineral 
kingdoms.  
 
Kaappu (Prevention)  
  
Siddha system prominently projects the prevention of diseases by the following methods 
1. Maintaining equilibrium of the three humours, is done by adopting noiilla neri 
technique  emphasized by siddhar Theraiyarsuch as doing vaanthi(vomiting) in six 
months once, paethi (purgation) every four months once,  nasiyam(nasal drops) 45 
days once and take oil bath weekly twice 
 
2. Avoiding stress and strain by doing Yogam technique 
 
3. Maintaining good mental health by doing meditation  
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Diet and Advices:  
Type Eat Avoid 
Vegetables  
 
Brinjal, Broad beans, Bitterguard, 
Lady‟s finger, Cluster beans, Onion, 
Turnip, Cauliflower, White pumpkin, 
Cabbage, Drumstick, Spadix of the 
Plaintain, Cucumber, Beans, Green 
vegetables, Pulses   
Unripe plaintain, Potato, Carrot, 
Beetroot, Elephant yam, 
Colachasia, Sweet pumpkin, 
Tubers, Tender coconut, Radish, 
Ground nut, Cashew nut    
 
Fruits   
 
 Apple, Papaya  ,Small Orange, 
Muskmelon ,  Pear, Guava  
Dates, Jackfruit, Dried fruits, 
Banana, Tinned fruits, Apple, 
Sapota, Mango, Guava   
Drinks   
 
Coffee, Tea without sugar, Soda, Lime 
juice, Soup, Tomato juice,  
Sugar items, Honey, Horlicks, 
Bournvita   
Non 
vegetarian 
foods    
Egg white 
 
Dry fish, Meat, Chicken   
 
Other foods   
 
Tomato, Mint, Coriander, Onion, 
Sambar, Gingelly oil, Sesame, cotton 
seed, rice bran and safflower oils .Salt 
up to 6g/day is permitted. Restrict 
pickles, papad and salty processed 
foods,   
Jaggery, Sugar candy, Badam, 
Cashew nut, Cake items, Ice 
cream, Betel, areca nut.   
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B.MODERN ASPECT 
DIABETES MELLITUS 
Diabetes mellitus: 
 
 Diabetes mellitus refers to a group of metabolic disorders that share the phenotype 
of hyperglycemia. Several distinct types of DM are caused by a complex interaction of 
genetics and environmental factors. Depending on the etiology of DM, factors contributing 
to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and 
increased glucose production. The metabolic deregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ system that impose a tremendous 
burden on the individual with diabetes and on the health care system. 
 
Epidemiology:  
 
The worldwide prevalence of DM has risen dramatically over the past two decades, 
from an estimated 30 million cases in 1985 to 382 million in 2013. Based on current trends 
the International Diabetes Federation projects that 592 million individuals will have 
diabetes by the year of 2035. Although the prevalence of type 1 and 2 DM is increasing 
worldwide, the prevalence of type 2 DM is rising much more rapidly because of increasing 
obesity, reduced activity levels. The countries with the greatest number of individuals with 
diabetes in 2013 are china (98.4 million), India (65.1 million), United states (24.2 
million).The prevalence of diabetes according to WHO criteria was 5.6% and 2.7% among 
urban and rural areas respectively.    
 
Classification: 
There are two broad categories of DM, designated 
Type 1 / IDDM (complete or near total insulin deficiency) 
Type 2 / NIDDM (variable degrees of insulin resistance, impaired insulin secretion, 
increased glucose production)  
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Etiologic classification: 
1.Type 1 / IDDM (complete or near total insulin deficiency) 
 A. immune mediated 
 B. idiopathic  
 
2.Type 2 / NIDDM (variable degrees of insulin resistance, impaired insulin secretion,  
increased glucose production) 
 
3. Other specific types: 
A. Genetic defect of beta cell development or function: 
 B. Genetic defect in insulin action 
 C. Disease of exocrine pancreas 
 D. Endocrinopathies 
 F. Drug or chemical induced 
 G. Uncommon forms of immune mediated diabetes 
4. Gestational diabetes mellitus 
 
Risk factors for type 2 Diabetes mellitus: 
 Family history of diabetes 
 Obesity (BMI>25kg/m
2
 ) 
 Physical inactivity 
Race / ethnicity 
Previously identified with IFG, IGT or hemoglobin A1c of 5.7-6.4% 
History of GDM or delivery of baby >4kg 
Hypertension 
HDL cholesterol level < 35mg/dl and TGL level  > 250 mg/dl 
Polycystic ovary syndrome 
History of cardio vascular disease 
 
 
 
 
19 
 
Anatomy of the pancreas:  
 Pancreas is a retro-peritoneal, fleshy organ, has both endo and exocrine function.  It 
is supra-umbilical, intrahepatic, posterio-abdominal, retroperitoneal organ, crossing the 
mid-line from right to the left.  As it‟s retroperitoneal, the organ does not move with 
respiration.  
 
 Generally, it has head, neck, body and tail.  The head of the pancreas is within the 
concavity of the duodenum.  The neck crosses the portal vein.  The body crosses the great 
vessels of the abdomen like, inferior vena cava, aorta, and left renal blood vessels.  The tail 
of the pancreas is in the left hypochondrium and, it contacts the hilum of the spleen.  The 
superior border is related to splenic artery.  
 
 The anterior border gives attachment of transverse mesocolon, this is a compound 
tubular gland showing endo and exocrine functions of which are correlated with pituitary 
gland.  
 
Microscopic anatomy of islets of – Langerhans  
 They are found more in the tail of the pancreas than in the other parts. They form 
about 1 – 2% of pancreatic weight.  There are about 2 millions of islets in human pancreas.  
Each islet has an epithelial mass, tunneled by labyrinthine capillaries.  The position of the 
islets is mostly within the lobules, rather than between them.  Each spheroid islet is 
surrounded by reticular membrane.  Islet tissue is arranged in irregular anastomosing 
cellular plates.  Their epithelial cords are separated by blood vessels.  A sphincter controls 
the blood supply.  The histological structure of the islets shows Alpha, Beta and Delta cells, 
of which,  
 
Alpha cells form 20% and glucagon secreting  
Beta cells form about 75% and insulin secreting  
Delta cells form about 5% and gastrin secreting 
  
 Beta cells are the source of insulin hormone.  The cells are polyhedral, the nuclei are 
centrally or eccentrically placed, the cytoplasm is grannular, filled with prominent secretary 
vacuoles containing few ribosomes.  The secretory granules show species variations.  In 
man they are spherical or elongated crystalline body.  
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INSULIN BIOSYNTHESIS, SECRETION, AND ACTION:  
Biosynthesis  
 Insulin is produced in the beta cells of the pancreatic islets. It is initially synthesized 
as a single-chain 86-amino-acid precursor polypeptide, preproinsulin. Subsequent 
proteolytic processing removes the amino terminal signal peptide, giving rise to proinsulin. 
Proinsulin is structurally related to insulin-like growth factors I and II, which bind weakly 
to the insulin receptor. Cleavage of an internal 31-residue fragment from proinsulin 
generates the C peptide and the A (21 amino acids) and B (30 amino acids) chains of 
insulin, which are connected by disulphide bonds.  
 
 The mature insulin molecule and C peptide are stored together and co- secreted from 
secretory granules in the beta cells. Because the C peptide is less susceptible than insulin to 
hepatic degradation, it is a useful marker of insulin secretion and allows discrimination of 
endogenous and exogenous sources of insulin in the evaluation of hypoglycemia.  
 
Human insulin is now produced by recombinant DNA technology; structural 
alterations at one or more residues are useful for modifying its physical and pharmacologic 
characteristics.  
 
Secretion:  
 Glucose is the key regulator of insulin secretion by the pancreatic beta cell, although 
amino acids, ketones, various nutrients, gastrointestinal peptides, and neurotransmitters also 
influence insulin secretion. Glucose levels >3.9 mmol/L (70 mg/dL) stimulate insulin 
synthesis, primarily by enhancing protein translation and processing, as well as inducing 
insulin secretion. Glucose stimulates insulin secretion through a series of regulatory steps 
that begin with transport into the beta cell by the GLUT2 glucose transporter.  
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Glucose phosphorylation by glucokinase is the rate-limiting step that controls 
glucose-regulated insulin secretion.  
  
         
  
  
    
 
 
 
Insulin glucagon 
 
   
 
 
Normal Blood Sugar Level  
 
            In normal persons, blood glucose level is controlled within a narrow range.  After 
the overnight fasting, in early morning, the blood glucose level ranges between 80 and 90 
mg/dl of blood.  Between first and second hour after meals (post prandial), the blood 
glucose level raises to 120-140 mg/dl. The glucose level in the blood is brought back to 
normal at the end of second hour after the meals.  
 
Necessity Of Regulation Of Blood Glucose Level  
 
Regulation of blood glucose level is very essential because, glucose is the only 
nutrient that can be utilized by tissues of brain, retina and germinal epithelium of the 
gonads.  
 
Role of Liver in the Maintenance of Blood Sugar Level  
Liver acts as an important glucose buffer system.  When blood glucose level 
increases after a meal, the excess glucose is converted into glycogen and stored in liver. 
Afterwards, when blood glucose level falls, the glycogen in liver is converted into glucose 
and released into the blood from the liver cells.     
Liver (glucose 
production and 
storage) 
 
Glucose Muscleand fat 
(glucose utilization) 
Brain 
Pancreatic islet 
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ROLE OF INSULIN IN THE MAINTENANCE OF BLOOD SUGAR LEVEL:  
 Insulin is the antidiabetic hormone, as it reduces blood sugar level.  It reduces the 
blood sugar level by the following actions.  
 
1. Transport and uptake of Glucose  
 
 When a food with excess amount of carbohydrate is taken, the blood sugar level is 
increased.  Immediately, pancreas secretes insulin.  The insulin facilitates the transport of 
glucose from the blood into the cells by increasing the permeability of cell membrane to 
glucose.  
 
 Insulin enhances the uptake of glucose by all the tissues particularly by liver, muscle 
and adipose tissues.  However, insulin is not required for glucose uptake in some tissues 
like brain (except hypothalamus), renal tubules, mucus membrane of intestine and red blood 
cells.  
 
2. Peripheral utilization of Glucose  
 
 The glucose entering the cells is oxidized by most of the cells immediately.  The rate 
of utilization depends upon intake of glucose, and the glucose utilization is enhanced by 
insulin.  
 
3.Storage of Glucose  
 
 Insulin promotes the rapid conversion of glucose into glycogen (glycogenesis) in 
muscle and liver.  Thus, glucose is stored in these two organs in the form of glycogen.  The 
insulin causes conversion of glucose into fatty acids.  
 
4. Inhibition of Glycogenolysis   
 
Insulin prevents the breakdown of glycogen into glucose in muscles and liver. 
 
5. Inhibition of Gluconeogenesis  
Insulin prevents gluconeogenesis i.e., it prevents the formation of glucose from 
proteins by following ways:  
a.Inhibiting the release of amino acids from muscle and   
b. Inhibiting  the activities of enzymes involved in gluconeogenesis.  
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Thus insulin decreases the blood sugar level in following manner;  
1. Facilitating the transport and uptake of glucose by the cells.  
2. Increasing the peripheral utilization of glucose.  
3. Conversion of glucose into glycogen in liver and muscle.  
4. Prevention of glycogenolysis.  
5. Inhibition of gluconeogenesis.  
 
Role Of Glucagon In The Maintenance Of Blood Sugar Level  
1. Glucagon increases glycogenolysis (breakdown of glycogen into glucose) in liver.     
And, the glucose thus formed is released from the liver cells into the blood. 
Glucagon does not induce glycogenolysis in muscle  
2. Glucagon increases gluconeogenesis (formation of glucose from proteins) in liver.     
It promotes gluconeogenesis by:  
 
a. a.Activating the enzymes which convert pyruvate into phosphoenol and pyruvate 
b. b.Increasing the transport of amino acids into the liver cells.  These amino acids 
are utilized for glucose formation.  
 
TYPE 2 DM 
(NON-INSULIN DEPENDENT DIABETES MELLITUS)  
Pathophysiology: 
 
Type 2 diabetes is due to insufficient insulin production from beta cells in the setting 
of insulin resistance. Insulin resistance, which is the inability of cells to respond adequately 
to normal levels of insulin, occurs primarily within the muscles, liver, and fat tissue.In the 
liver, insulin normally suppresses glucose release.   
 
However, in the setting of insulin resistance, the liver inappropriately releases 
glucose into the blood. The proportion of insulin resistance versus beta cell dysfunction 
differs among individuals, with some having primarily insulin resistance and only a minor 
defect in insulin secretion and others with slight insulin resistance and primarily a lack of 
insulin secretion.  
 
     Other potentially important mechanisms associated with type 2 diabetes and insulin 
resistance include: increased breakdown of lipids within fat cells, resistance to and lack 
ofincretin, high glucagon levels in the blood, increased retention of salt and water by the 
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kidneys, and inappropriate regulation of metabolism by the central nervous 
system.However, not all people with insulin resistance develop diabetes, since an 
impairment of insulin secretion by pancreatic beta cells is also required.   
 
Prevention: 
Onset of type 2 diabetes can be delayed or prevented through proper nutrition and 
regular exercise. Intensive lifestyle measures may reduce the risk by over half. The benefit 
of exercise occurs regardless of the person's initial weight or subsequent weight loss. 
Evidence for the benefit of dietary changes alone, however, is limited,with some evidence 
for a diet high in green leafy vegetables and some for limiting the intake of sugary drinks.In 
those with impaired glucose tolerance, diet and exercise either alone or in combination with 
metformin or acarbose may decrease the risk of developing diabetes. Lifestyle interventions 
are more effective than metformin.  
 
CLINICAL FEATURES OF DIABETES  
 
The clinical features of the two main types of diabetes are compared below.  
Comparative Clinical Features Of Type 1 And Type 2 Diabetes  
      TYPE 1  TYPE 2 
Age at onset                                       <40 years      >50 years  
Duration of symptoms                     Weeks                      Months to years  
Body  weight                                       Normal or low           Obese  
      TYPE 1  TYPE 2 
Ketonuria                                            Yes                         No  
Rapid death without Treatment  
with insulin                                          Yes                           No  
Auto antibodies                              Yes                            No  
Diabetic complications at diagnosis  No                            25%  
Family history of diabetes                 Uncommon                Yes  
  
The classical symptoms of thirst, polyuria, nocturia and rapid weight loss are 
prominent in type 1 diabetes, many of whom are asymptomatic or have non-specific 
complaints such as chronic fatigue and malaise.  
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 Uncontrolled diabetes is associated with an increased, susceptibility to infection and 
patients may present with skin sepsis (boils) and genital candidiasis and complain of 
pruritus vulvae and balanitis.  
 
 Patients with type 1 diabetes often have no physical signs attributable to diabetes, 
but weight loss is common.  
 
 The physical signs in patients with type 2 diabetes at diagnosis depend on the mode 
of presentation. More than 70% are overweight, and obesity may be central (truncal or 
abdominal). Obesity is less common in developing countries.  
 
Hypertension is present in 50% of patients with type 2 diabetes. Although 
hyperlipidaemia is also common, skin lesions such as xanthelasma and eruptive xanthomata 
are relatively rare.  
 
Criteria for the diagnosis of Diabetes mellitus: 
1. Symptoms of diabetes 
2. Fasting / random / post prandial blood glucose concentration 
3. HbA1c 
4. 2 hours plasma glucose during an oral glucose tolerance test 
 
LABORATORY EVALUATION  
If the patient is a known diabetic, the following tests are to be advised  
 Fasting blood sugar (FBS)   
 Postprandial blood sugar (PPBS)  
 Glycated haemoglobin (HbA1c)  
 Blood urea  
 Serum creatinine 
 Urine protein 
 Haemogram   
 Urine complete examination 
 Lipids (total cholesterol, triglycerides, HDL, LDL)   
 Liver function tests (LFT)  
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If the patient is not a known diabetic, the following tests can be advised  
 Glucose tolerance test (GTT)  
 Glycated haemoglobin (HbA1c) 
 Blood urea  
 Serum creatinine  
 Urine P/C ratio   
 Urine complete examination   
 Lipids (total cholesterol, triglycerides, HDL, LDL)   
 Liver function test(LFT)  
 ECG  
 
COMPLICATIONS OF DIABETES MELLITUS   
1. Acute Complications  
a. Diabetic ketoacidosis (DKA)  
b. Nonketotic hyperosmolar state (NKHS)  
c. Hyper osmolar coma    hypoglycemia  
Diabetic Ketoacidosis:  
 
 Diabetic ketoacidosis is a major medical emergency and remains a serious cause of 
morbidity, principally in people with type 1 diabetes. The average mortality in developed 
countries is 5-10% and is higher in the elderly.  
 
A clear understanding of the biochemical basis and pathophysiology of this problem 
is essential for its efficient treatment.  
 
Ketoacidosis is caused by insulin deficiency and an increase in catabolic hormones, 
leading to hepatic over-production of glucose and ketone bodies.  
 
The cardinal biochemical features of diabetic ketoacidosis are:  
a. hyperglycaemia  
b. hyperketonaemia  
c. metabolic acidosis.  
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Hyperglycaemia causes a profound osmotic diuresis leading to dehydration and 
electrolyte loss, particularly of sodium and potassium. The metabolic acidosis forces 
hydrogen ions into cells, displacing potassium ions, which may be lost in urine or through 
vomiting.  
 
About half the deficit of total body water is derived from the intracellular 
compartment and occurs comparatively early in the development of acidosis with relatively 
few clinical features; the remainder represents loss of extra cellular fluid sustained largely 
in the later stages. It is at this time that marked contraction of the size of the extra cellular 
space occurs, with haemo concentration, a decreased blood volume, and finally a fall in 
blood pressure with associated renal ischaemia and oliguria.    
 
Every patient in diabetic ketoacidosis is potassium-depleted, but the plasma 
concentration of potassium gives very little indication of the total body deficit. Plasma 
potassium may even be raised initially due to disproportionate loss of water and catabolism 
of protein and glycogen.  
 
Nonketotic Hyperosmolar State:  
 
Clinical Features NKHS is most commonly seen in elderly individuals with type 2 
DM. Its most prominent features include polyuria; orthostatic hypotension; and a variety of 
neurologic symptoms that include altered mental status, lethargy, obtundation, seizure, and 
possibly coma.  
 
The prototypical patient is a mildly diabetic, elderly individual with a several week 
history of polyuria, weight loss, and diminished oral intake that culminates in mental 
confusion, lethargy, or coma. The physical examination reflects profound dehydration and 
hyperosmolality and reveals hypotension, tachycardia, and altered mental status.  
 
NKHS is often precipitated by a serious, concurrent illness such as myocardial 
infarction or stroke. Sepsis, pneumonia, and other serious infections are frequent 
precipitants and should be sought thoroughly. Finally, the development of NKHS can be 
associated with the use of certain medications (thiazide diuretics, glucocorticoids, and 
phenytoin).  
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2. Chronic Complications of Diabetes Mellitus  
a. Microvascular:  
 Eye disease  
 Retinopathy(nonproliferative/proliferative)  
 Macular edema  
 Cataracts  
 Glaucoma  
 Neuropathy  
 Sensory and motor (mono- and polyneuropathy)  
 Autonomic  
 Nephropathy.  
b. Macrovascular:  
 Coronary artery disease  
 Peripheral vascular disease  
 Cerebrovascular disease  
c. Other:  
 Gastrointestinal (gastroparesis, diarrhoea)  
 Genito urinary (uropathy/sexual dysfunction)  
 Dermatologic  
DIABETIC RETINOPATHY:  
 
Diabetic retinopathy is the most common cause of blindness in adults between 30 
and 65 years of age in developed countries.  
 
Pathogenesis:  
 
Hyperglycaemia increases retinal blood flow and metabolism and has direct effects 
on retinal endothelial cells and pericytes, loss of which impairs vascular autoregulation.the 
resulting in uncontrolled blood flow increases production of vasoactive  substances and 
endothelial cell proliferation, resulting in capillary closure. This causes chronic retinal 
hypoxia and stimulated production of growth factors, including vascular endothelial growth 
factor (VEGF). VEGF acts via proteinkinase  C to stimulate endothelial cell growth 
(causing new vessel formation) and increased vascular permeability (causing exudative 
damage).    
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Clinical Features Of Diabetic Retinopathy:  
1. Microaneurysms  
2. Retinal haemorrhages  
3. Exudates  
4. Cotton wool spots  
5. Venous changes  
6. Neovascularisation  
7. Pre-retinal haemorrhage  
8. Vitreous haemorrhage  
9. Fibrosis  
 
INTRARETINAL MICROVASCULAR ABNORMALITIES  
Intraretinal microvascular abnormalities (IRMA) are dilated, tortuous capillaries 
which represent the remaining patent capillaries in an area where most have been occluded.   
 
Neovascularisation:  
 
This may arise from the venous circulation on the optic disc or the retina in response 
to areas of ischaemic retina. retinal detachment can occur due to contraction of adhesions 
between the vitreous and the retina.  
 
Venous Changes:  
 
These include venous dilatation (an early feature probably representing increased 
blood flow), „beading‟ (sausage-like changes in calibre) and increased tortuosity including 
„oxbow lakes‟ or loops.  
 
Cataract:  
 
Cataract is a permanent lens opacity and is the most common cause of visual 
deterioration in the elderly population.  
 
The lens thickens and opacifies with age, and the increased metabolic insult to the 
lens in people with diabetes causes these changes to accelerate and occur prematurely. Very 
rarely, a type of cataract specific to diabetes occurs in young patients with poorly controlled 
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diabetes, called a „snow-flake‟ cataract. This does not usually affect vision but tens to make 
fundal examination difficult.  
 
Renal Complications Of Diabetes Mellitus:  
 
The nephropathy that develops in type 2 DM differs from that of type 1 DM in the 
following respects:  
 
a. Microalbuminuria or over nephropathy may be present when type 2 DM is diagnosed, 
reflecting its long asymptomatic period;  
b. Hypertension more commonly accompanies microalbuminuria or nephropathy in type 
2 DM 
c. Micro albuminuria may be less predictive of progression to over nephropathy in type 2 
DM. Finally, it should be noted that albuminuria in  type 2 DM may be secondary to 
factors unrelated to DM, such as hypertension, congestive heart failure, prostate 
disease, or infection.  
Other renal problems may also occur in individuals with DM. Type IV renal tubular 
acidosis (hyporeninemic hypoaldosteronism) occurs in many individuals with DM  
 
NEUROPATHY AND DIABETES MELLITUS  
Diabetic neuropathy occurs in approximately 50% of individuals with long-standing 
type 1 and type 2 DM. It may manifest as polyneuropathy, mononeuropathy, and/or 
autonomic neuropathy.  
 
a.Polyneuropathy/Mononeuropathy:  
 
The most common form of diabetic neuropathy is distal symmetric polyneuropathy. 
It most frequently presents with distal sensory loss. Hyperesthesia, parathesia, and pain also 
occur. Any combination of these symptoms may develop as neuropathy progresses. 
Physical examination reveals sensory loss, loss of ankle reflexes, and abnormal position 
sense.   
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b. Diabetic polyradiculopathy  
c. Mononeuropathy (dysfunction of isolated cranial or peripheral nerves)  
d. Autonomic Neuropathy  
Cardiovascular Morbidity and Mortality:  
 
Cardiovascular disease is increased in individuals with type 1 or type 2 DM. The 
Framingham Heart Study revealed a marked increase in several cardiovascular diseases in 
DM including peripheral vascular disease, congestive heart failure, coronary artery disease, 
myocardial infarction, and sudden death (risk increase from one- to fivefold).  
 
The extremely high frequency of underlying cardiovascular disease in individuals 
with diabetes (especially in type 2 DM).The absence of chest pain (“silent ischemia”) is 
common in individuals with diabetes.  
 
Hypertension:    
 
Hypertension can accelerate other complications of DM, particularly cardiovascular 
disease and nephropathy. Hypertension therapy should first emphasize life-style 
modifications such as weight loss, exercise, stress management, and sodium restriction.  
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YOGAM 
Siddha science not only comprise the science of medicine but also every blessed 
theme on which the perpetual well-being of the whole human race is dependant. Yogam is 
one of the kayakalpam method that preserve physical and mental health. The term yogam 
means “union”.Siddhars have defined yoga as an art which controls the mind by preventing 
it from getting distracted through sense organs and by uniting it with the divinity after 
realizing the truth of eternal bliss. Yogic physical culture would give vibrant health, real 
strength, the strength of the vital organs and muscular exercises, physical force and shape. 
Only in this human birth one can get rid of sins and by virtue of good deeds get 
deeply absorbed in the pathways of yoga to attain the state of unity with entity. There is no 
system in the world to equal the yogam in giving health and simultaneously powers 
intellectual. 
RELATIONSHIP BETWEEN YOGA AND AADHARANGAL (CHAKARAS): 
The life energy pranan travels in the subtle body through a series of channels called 
nadis. These channels spins at a particular points which gets vortexes of energy that 
correspond to the chakras in the body. They are namely mooladharam,swasthitanam, 
manipooragam, anagatham, visuddhi, akkinai.These chakras are nothing  but the storehouse 
of the finer aspects of solidified and mental modifications of the mind. They are control 
centres in the body and are related to different sections in the spine  
Coccyx : moolatharam 
Sacrum : swadhitanam 
Lumbar  : manipooragam 
Dorsal  : anagatam 
Cervical : visuddhi 
Akkinai  : located between the eyebrows. 
Each chakra regulates specific bodily systems in the body. For a balanced healthy 
life all the chakras must provide right amount of energy to the body. Our way of living in 
the world is highly dominated by the imbalanced functioning mainly of the lower three 
chakras.The pathway of the prana vayu gets affected in diseased condition of the body. This 
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in turn stagnates the the flow of pranan in the chakras. Practising yogasanam revitalizes and 
channelizes the flow of life energy. 
Siddhar‟s science declares 64 kinds of yoga. Siva raja yogam and karpa yogam are 
one among them. 
Mr;rg;gh mWgj;JehYNahfk; mlq;fYNk ghbitj;jhu; rpj;jnuy;yhk; 
Vr;rg;gh capu;fisAq; nfhy;yntd;W ,d;gKld; mk;gpfh Nahfnkd;W 
thr;rg;gh ehitAe;jhd; NkNyA+d;wp tbthd tha;Tfis fl;Lk;NghJ 
Ngr;rg;gh fz; njupf;Fk; tha;TjhDk; gpupaKld; raNuhfkhe;jhNd 
ePjpaid<ub Tyhtpte;Nj epyTk; Mjdj;jpy; kPz;Lk; nghUe;jp 
XJrhjidapy; cWjpNahbUg;gJ Nahfpau;f; fpay;gjhkd;Nw 
-Rg;gpukzpau; Qhdk; 10 
Siddhar agathiyar mentions about 9 asanams in his text Agathiyar paripooranam 
rpj;jKld; Nektif gj;Jf;fz;L 
njspj;Jrpt NahfkJ jpwkha;epw;f 
nte;jpAs;s Mrde;jh ndhd;gjg;gh 
tpguKs;s nrhy;YfpNwhd; tpUk;gpf;NfS 
gj;jpAs;s nfhj;jpfq;Nfh KfKk;gj;kk; 
gjpthd gPuk;gj;jpuQ; rpq;fnkhLKj;j 
Kj;jpAs;s kA+unkhL RfkJTike;jh 
Kjyhd etf;fpufk; xd;gJ MrdNk 
Mrdkha; epd;wnjhU xd;gijAq;fz;L 
mjpypUe;J jtRrpt NahfhQ;nra;jhy; 
G+rzkha; epd;wpyq;F khrde;jhd;ike;jh 
Gj;jpAl dhrdNk ypUe;Jnfhz;L 
thridaha; kdJfe;J thrpghu;j;J 
kdkfpo;e;J rptNahf epiyapy;epd;W 
NerKld; gpuhzhaQ; nra;Jnfhz;L 
                      epr;rakha;f; fw;G+u jPgk;ghNu. 
     -mfj;jpau; gupG+uzk; 1200  
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Siddhar thirumoolar the renowned sage who authored Thirumanthiramhas assured 
that all human disease can be cured through yogasanam and pranayamam. Yogam focuses 
on ashtanga yogam namely Iyamam , Niyamam, Pranayamam, Asanam, Prathiagaram, 
Tharanai, Dhiyanam, Samathi.   
 
fhzNt ml;lhq;f nkl;Lq;NfS 
    fUthfr; nrhy;YfpNwd; fz;Lnfhz;L 
G+zNt ,kankhL Nekike;jh 
Gj;jpAl dhrdKk; gpuhzhae;jhd; 
NjhzNt jhuhizAk; gpuj;jpahfhuk; 
    #l;rnkd;w rkhjpnahL jpahdk;gj;Jk; 
NgzNt nal;Lklh ml;lhq;fNahfk; 
    ngUikAs;s fhtpaj;ijf; fz;LNjNw. 
-mfj;jpau; gupG+uzk; 1200  
Iyamam means good thoughts, niyamam means good deeds, asanam means posture, 
pranayamam means regulating breath, prathiyagaram controlling the mind, tharanai means 
concentration, dhyanam means thinking about one aspect, Samadhi attained of heavenly 
stage.  
Thirumoolar have mentioned that there are numerous asanam but stresses only eight 
among them soththirasanam, gomukhasanam, padmasanam, veerasanam, simhasanam, 
bhadrasanam, mukthasanam and sukhasanam. 
gj;jpuk; NfhKfk; gq;fak; Mrdk; 
nrhj;jpuk; tPuk; Rfhjdk; XNuOk; 
cj;jkhk;KJ Mrdk; vl;nll;Lg; 
gj;njhL E}W gy MrdNk. 
-jpUke;jpuk; 
  
According to thirumoolar, regular practise of yogasanas can monitor the excess or shortage 
of pitham, vatham and kabam. He also states that when yoga is practised early in the 
morning pitham is reduced, causing the body to be more relaxed. When yoga is practised 
around mid-day vatham is controlled and in the evening kabam is controlled. 
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Mjdj;jpUe;Nj rhjidGupe;jhy; mlq;fplhg; nghwpGydlq;Fk; 
Mjdj;jpUe;Nj rhjidGupe;jhy; mlq;fpL kNdhtp~aq;fs; 
Mjdj;jpUe;Nj rhjidGupe;jhy; mwpT mwpahikf nshopAk; 
rhjidGupe;jhy; mfz;ltP liltJeprNk 
-Rg;gpukzpau; Qhdk; 1200 
 
Asanas are helpful in the practice of yoga in the following ways, 
1. An uncommon power of fortitude and control of the different muscles of the body 
are acquired. 
2. The entire physical system id brought under the control of will in a vivid manner. 
3. The body is kept free from all impurities with the nervous system kept unclogged for 
the free exercise of breathing. 
4. Disease are cured and the way of the attainment of health and perpetual life is made 
clear. 
5. The five senses can be controlled, rising thoughts averted mind concentrated 
6. Some of the primary differences between pure exercise and yoga are 
 
 Exercise Yogasanam 
Is practiced after muscle are stronger May be practiced at any age 
Takes a long time for results Produces faster results 
Requires greater food intake Needs less food intake 
Requires equipment Needs no equipment 
Builds muscle  Activates glands 
Tires mind / body Rejuvenates mind / body 
Causes shortness of breath Elongates breathing 
Creates aggression Creates passivity 
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Yogasanam techniques and benefits: 
Each Yogasanam is indicated for a definite effect in a particular region of the system 
by stimulating the internal organs to function in a normal way and to coordinate bodily 
functions. Rejuvenation / regeneration of cells of pancreas due to abdominal stretching 
during yogam , which may increase utilization and metabolism of glucose in peripheral 
tissues, liver, and adipose tissues through enzymatic process. More active practices 
followed by relaxing ones lead to deeper relaxation than relaxing practices alone, Muscular 
relaxation, development and improved blood supply to muscles might enhance insulin 
receptor expression on muscles causing increased glucose uptake by muscles and thus 
reducing blood sugar. Yogam postures can lead to improvement in the sensitivity of the beta 
Cells of the pancreas to the glucose signal and also the improvement in insulin sensitivity in 
turn can be due to the cumulative effect of performing the postures. yogam may also lower 
oxidative stress and blood pressure; enhance pulmonary and autonomic function, mood, 
sleep, and quality of life; and reduce medication use in adults with Diabetes Mellitus.  
Suryavanakkam: 
STEP 1: 
Stand straight, facing forward with normal breathing, keep the feet together, the 
toes, and heels in the straight line, big toes and centre of the inner ankle touching each 
other. Keep the weight evently on the heels. 
Keeping the leg facing forward, join both the palms together.Place the hand near the 
chest with the thumb touching the middle of the chest Spread the elbow outward from the 
body and take a deep inhalation and slow exhalation. 
STEP 2 
 Keeping the knees straight and heel down, bring the thighs and hip forward and start 
arching your body backwards.Inhale while increasing the arch slowly by raising the arms 
and stretched back over the head.When your hands are on both sides of your head, allow 
your upper arms to touch your ears. 
STEP 3 
Keeping the knee straight and heels down, bend the body forward.Exhale while you 
bend your body forward and down.Keep your hands flat on the floor at the sides of the legs. 
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STEP 4 
Extend your left leg back while inhaling and drop the knee to the floor.Bend your 
right knee between the hands, the right thigh touches the right side of the chestPalms and 
the right foot must be in the same lineConcentrate at the centre of the eyebrow by pushing 
your head backward. 
STEP 5 
Press the palms on the floor, and simultaneously raise the back and lower the head 
between the arms.The heels should always be flat on the floor maintain this posture. 
STEP6 
Exhaling bring the right leg back to join with the left leg with chin touching the 
ground. 
STEP 7 
Raise the chest upwards with help of your hands and arch the spine along your head 
backward.Stretch your foot backwards, keeping your knees straight.Repeat steps 5 to 1. 
Benefits: 
 It increases blood circulation to all parts of the body. It decreases degenerative 
changes in the joints. Improves the nervous stimulation  
 Improves digestion  
 Improves eyesight 
 It increases immunity 
 It control diabetes. 
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Bhujangasanam 
 Lie on your chest with the palms down and fingertips in line with the shoulder. 
 Applying minimum pressure on your hands, rise your head high and bend back like 
a snake breathe normally. 
 Then lower your head slowly. 
 Hold for 15 seconds. 
Benefits: 
 The stomach muscles are pulled and blood flows freely to the front of the body. 
 The backbone gets stronger. 
 The chest expands and the ribs get strengthen. 
 
 
Patchimothasanam: 
 Sit up straight and keep both legs together. 
 Stretch your arms up close to the side of the head near the ears. 
 Inhale and bend forward to hold your feet with your hands. 
 Then try to touch your knees with your face. 
 Stay in this position for 10 seconds. 
 
Benefits 
 Stomach muscles will get stronger. 
 Liver spleen stomach pancreas will be reactivated .when performed correctly any 
disease of the organs will recede. 
 Appetite will become normal. 
 Cures diabetes. 
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Yoga mudra: 
 Sitting in Padmasanam, fold your palms together comfortably behind your backs, or 
touch elbows with opposite hands. 
 Your chin should touch chest. 
 In this position exhale and bend forward so that your forehead touches the ground. 
 After being in position for few seconds, inhale and rise our head and sit erect. 
Benefits: 
 The muscles in the back bones and stomach organs feel refreshed. 
 The liver and spleen will feel the pleasure and begin to work well. 
 Cures diabetes. 
 The waist line reduces and spine is straightened. 
 Cures indigestion and constipation. 
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Halasanam: 
Procedure: 
 Lie on your back, keep the leg in contact and stretch your hands on the sides of the 
body. 
 Keeps the palm touching the floor. Inhale a little, raise the legs above the waist and 
bend them above the body backwards. Touch the floor with the toes have touched 
the floor, bend the back well and press the chin with the chest. 
 The back of the head (occipital region) and neck should touch the floor. 
 Extend the legs to the back of the head as for as they would go. 
  Stimulates visuddhi chakram. 
Benefits:  
 Stretches all muscles and ligaments in the practitioner‟s calves and thighs, resulting 
in greater flexibility. 
 Therapeutic for leg cramps. 
 It stimulates thyroid, parathyroid, throat and abdominal organs. 
 Therapeutic for menopause, infertility, insomnia, headache, sinusitis. 
 Promotes good digestion. 
 Helps to relieve gas and upper/lower back pain or discomfort. 
 Relieves stress and fatigue.
 
Bavanamuktasanam: 
 Method 
 Lieflatonyourbackandkeepthelegsstraightandbreathedeeply. 
 Inhaleslowlyandliftthelegsandbendintheknee.Bringupwardstothe 
chesttillyourthightouchestostomach 
 Hugyourknees inplaceand lock yourfingers. 
 Trytotouchthekneewithyournosetip.Holdthispositionforfewseconds 
 Nowexhaleslowly andcomebackto theinitialposition 
41 
 
Benefits 
 It cures acidity, indigestion, constipation. 
 Helpfulforarthritispainandheartproblems. 
 Strengthensbackmuscleandcuresbackpain. 
 Itgivesflatstomach. 
 Verybeneficialforreproductive organandformenstruationdisorder. 
 Specifically stimulatesManipurakam chakram. 
 
Vakrasanam: 
Method: 
 Sit down stretching your legs forward on the ground. 
 Keep your hands beside your thighs or buttocks. 
 Bend your right leg straight and stretched. 
 Keep the left foot beside the right knee and the left knee raised upward. 
 Inhale and raise the arms shoulder high, keeping the elbows straight. 
 Exhaling, twist to the left, place the right arm by the outer side of the left knee and 
hold the left ankle with the right hand. 
 Take the left hand behind the back keeping the palms on the floor. 
 Look backward towards the left side. 
 Hold on the position. Practise both sides. 
 
Benefits: 
 Increases the elasticity of the spine and tones the spinal nerves. 
 Stretches the muscles. 
 Helps to get relief in stiffness of vertebrae. 
 Massages the abdominal organs. 
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 Reduces belly fat. 
 Regulates the secretion of digestive juices useful for different digestive disorders. 
 Loosens the hip joints, relieving stiffness. 
 Flab on the lateral side of the abdomen gets reduced. 
 Specifically stimulatesManipurakam chakram. 
 
 
 
Padmasanam: 
 Cross your legs over the left and right thighs. 
 Both the knee joint should touch the floor. 
 Both heels should touch the abdomen. 
 Both hands should be in chin mudra. 
 
Benefits: 
 Improves the blood flow to the abdomen. 
 Improves appetite. 
 This is a good posture to perform pranayamam 
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 Naadisuthi pranayamam 
   Sit in a comfortable posture (Padmasanam, sugasanam, vajrasanam) 
 Lefthandinchinmuthraiwithclosedeyes. 
 Closetheright nostrillusingrightthumb. 
 Inhale slowly and deeply through the left nostrils, followed by holding the air for 
few seconds by closing the right nostrils by thumb and left nostrils by ring and little 
finger of right hand.Exhale through right nostrils 
 Inhale by right nostrils holding the air by closing both nostrils exhale through left 
nostrils.Repeat the same for few minutes 
 
 
 
Savasanam (shanthi aasanam): 
Method: 
 Lie down on the floor with an even surface. 
 Palm facing upward and half a foot gap in between the heels, keep the legs in relax 
manner. 
Benefits:Relieves physical and mental tiredness.
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SYZYGIUM CUMINI 
Botanical Name :  Syzygium cumini 
Family   :  Myrtaceae 
Part used  :  Bark 
 
Organoleptic Characters 
Taste   : Thuvarppu 
Potency  : Thatpam 
Pirivu   :  Kaarppu 
 
Chemical Constituents: 
Anthocyanins, glucoside, ellagic acid, isoquercetin, kaemferol and myrecetin. The 
seeds are claimed to contain alkaloid, jambosine, and glycoside antimellin 
General properties: 
MrpaNeha; fhrk; mrpu;f;fuQ;R thrtpid 
NfrKW ghy fpufNeha;-Ngrupa 
khtpaq;f yhQ;rdkpt; td;gpzpna yhNkFk; 
ehtYW gl;ilaj dhy;. 
Medicinal uses:  
The bark is astringent, sweet, sour, acrid, refringerant, carminative, diuretic, 
digestive anthelmintic febrifuge 
 
ACACIA NILOTICA 
Botanical Name : Acacia nilotica 
Family   : Mimosaceae 
Part used  : Bark 
Organoleptic Characters 
Taste   : Thuvarppu 
Potency  : Thatpam 
Pirivu   :Inippu 
45 
 
 
ChemicalConstituents: 
Bark yields several polyphenol compounds,,catechol, epicatechin, epigallocatechin, 
quercetin,gallic acid, leucocyanidingallate, sucrose, tannin, m-digallic and chlorgenic acid 
Medicinal uses: 
Bark decoction is used to gargle in sore throat and tooth ache; dry powder applied 
externally in ulcers. 
 
SALACIA RETICULATA 
Botanical Name : Salacia reticulata 
Family   : Hippocrateaceae 
Part used  : Root 
 
Organoleptic Characters 
Taste   :Thuvarppu 
Potency  :Thatpam 
Pirivu   :Kaarppu 
 
Chemical Constituents: 
Triterpenes, hydrocarbons and sitosterol,mangiferin, kotalanol, and salacinol 
General properties: 
jPjpy; clyopQ;rpy; nra;Aq; Fzq;Nfsha;! 
xJkJ Nkf nkhopg;gjy;yhy;-thjj;jpy; 
te;jryk; gpj;jry khfgr;r ye;jhfj; 
njhe;jry Kk;Nghf;FQ; nrhy; 
Medicnal uses: 
The roots are acrid, bitter,thermogenic,urinary astringent,anodyne, anti-
inflammatory, depurative, liver tonic and stomachic 
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TERMINALIA ARJUNA 
Botanical Name: Terminalia arjuna 
Family  : Combretaceae 
Part used : Bark 
 
Organoleptic Characters 
Taste  : Thuvarppu 
Potency :Thatpam 
Pirivu  :Karppu 
 
Chemical Constituents: 
 
Arjunolicacid,tomentosic acid,b-sitosterol,ellagic acid, saponin, 
leucodelphidin,arjunine.arjunetin,tannin, pyrocatechol. 
General properties: 
xjnkD ePupopit Nahl;Lk; gpuNkfq; 
fhjnkd Nthlf; flj;Jq;fhz;-Nghj 
kaf;f nkhLjhf khwhr; Ruj;jpd; 
jaf;fkWf; Fk; kUjQ; rhw;W 
Medicinal uses: 
The barks are acrid, astringent, sweet, cooloing, demulcent, cardiotonic, styptic, 
antidysentic, lithotryptic and expectorant 
TERMINALIA BELLERICA 
Botanical Name: Terminalia bellerica 
Family  : Combretaceae 
Part used : Seeds  
 
Organoleptic Characters: 
Taste  : Thuvarppu 
Potency : Veppam 
Pirivu  : Inippu 
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General properties: 
Mzpg;nghd; Nkdpf; foFk; xspAkpFk; 
Nfhzpf;nfhs; thjgpj;jf;nfhs;ifNghk;-jhdpf;fha; 
nfhz;ltu;f;F NkfkWk; $wh mdaw;wzpAk; 
fz;ltu;f;F thjk;Nghk; fhz;. 
 
Chemical Constituents: 
Fruit contains about 17%tannin and β-sitosterol, gallic acid, ellagic acid, ethyl 
gallate, galloyl glucose and chebulagic acid. 
 
Medicinal uses: 
The fruits are astringent, acrid, sweet, thermogenic, anodyne, styptic, narcotic, 
digestive, anthelmintic, aperient, ophthalmic, antipyretic and rejuvenating. 
 
TERMINALIA CHEBULA 
Botanical Name : Terminalia chebula 
Family   : Combretaceae 
Part used  : Seeds  
Organoleptic Characters 
Taste   : Thuvarppu 
Potency  : Veppam 
Pirivu   :Inippu 
 
Chemical Constituents: 
Fruits contain 30% astringent substance; astringency due to the characteristic 
principle chebulinic acid also contain 20-40 % gallic acid, resin etc. And a purgative 
glycoside of athroquinone derivative. 
General properties: 
Jhil foj;jf;fp jhY Fwpaptplg; 
gPil rpypgjKw; NgjpKlk; -Milnal;lhj; 
J}ykpb Gz;thj Nrhzpfh khiyapuz; 
lhykpb Nghk;tupf;fh ahy;  
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Medicinal uses: 
Chebulinic acid exhibits antispasmodic action on smooth muscle similar to 
papaverine. The fruits are astringent,sweet, acrid,bitter, sour, thermogenic,antiseptic,and 
stomachic. 
PHYLLANTHUS EMBLICA 
Botanical Name :Phyllanthus emblica 
Family   : Euphorbiaceae 
Part used  : Seeds 
 
Organoleptic Characters 
Taste   :Thuvarppu,Pulippu,Inippu 
Potency   :Thatpam 
Pirivu    : Inippu 
 
Chemical Constituents: 
The major amino acids are alanine, aspartic acid, glutamic acid, lysine, and proline. 
General properties: 
Mftd yQ;rrpm rpu;f;nfd;G Uf;fpfz;Nzha; 
Jhf Kjputpj;je; jhJ e~;lk;-Nkfdj;jpd; 
,y;ypKs;sp NghyUfy; vz;fh kpatpawq;fk; 
ney;ypKs;sp ahw;Ngh epid. 
 
Medicinal uses: 
The fruits are sour, astringent, bitter, acrid, cooling, carminative, ophthalmic, 
stomachic, laxative, diuretic antipyretic. 
STRYNCHNOS POTATORUM 
Botanical Name : Strynchnos potatorum  
Family   :Logainaceae 
Part used  :Seeds 
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Organoleptic Characters 
Taste   : Kaippu 
Potency  : Veppam 
Pirivu   :Kaarppu 
 
Chemical Constituents: 
Loganin, mannose, sucrose, arachidonic, lignoceric, linoleic, oleic, palmitic, and 
stearic acids, β-sitosterol, stigmasterol, 
 
General properties: 
Njw;whk; tpijaJjhd; jPgdj;ijg; Nghf;Fkdy; 
Mw;WkpU fz;Zf; fUkUe;jhk;-$w;w  
apUj;Jq; fpupr;ryj;ij vq;Fkpyh Njhl;Lq; 
FUj;Jt Kz; lhf;Fq; Fwp.  
 
Medicinal uses: 
The seeds are sweet, bitter, astringent, demulcent, emetic, diuretic, refrigerant, 
appetiser, tonic and water purifier. 
ARECHA CATECHU 
Botanical Name : Arecha catechu 
Family   : Palmaceae 
Part used  : Seeds 
Organoleptic Characters 
Taste   : Thuvarppu 
Potency  : Veppam 
Pirivu   : Kaarppu 
Chemical Constituents: 
The seeds contain tannin, catechin (70%in the young fruit 15-20%in over-ripe 
fruits), lipids consisting of laurin, olein, myrstin; glucides 50-60%alkaloids, arecoline, 
arecaidine, guvacine and guvacoline. 
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Medicinal uses: 
The pericarp is effective in the treatment of flatulence, oedema, dysuria, and 
hyperemesis of pregnancy. The kernel is used to treat diarrhoea ad dysentery. Arecoline 
induces papillary contraction and decreases ocular tension in glaucoma. 
FICUS RACEMOSA 
Botanical Name :Ficus racemosa 
Family   : Moraceae 
Part used  : Bark                                                                                   
Organoleptic Characters 
Taste   : Thuvarppu 
Potency  : Thatppam 
Pirivu   : Inippu 
 
Chemical Constituents: 
Glycosides, β-sitosterol,lupeol, tannins,psoralenes 
General properties: 
tPW fLg;gpuj;jk; ntz;rPj uj;jnkhL 
ehWtpu zq;fnsyhk; ehlhthk; -$Wq;fhy; 
mj;jpjU Nkfk;Nghk; MapioNa! vQ;Qhd;Wk; 
mj;jpg;ghw; gl;ilf; fwp. 
 
Medicinal uses: 
The extract of the fruit is used in diabetes, leucoderma and menorrhagia.It is used 
locally to relieve inflammation of skin wounds, lymphadenitis, sprains, fibrousitis. 
 
CASSIA AURICILATA 
Botanical Name : Cassia auriculata 
Family   : Fabacae  
Part used  : Bark 
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Organoleptic Characters 
Taste   :Thuvarppu 
Potency  :Thatppam 
Pirivu   :Inippu 
Chemical constituents: 
Alkaloids, tannins flavonoids, glycosides, saponins 
General properties: 
nrhy;Yjw;F kl;Nlh njhiyahj NkfePu; 
vy;yh nkhopf;F nkuptfw;W-nky;ytr 
khthiug; gk;guk;Ngh yhl;Le; njhopyzq;Nf! 
Ahthiu %yp aJ. 
 
Medicinal uses: 
The stem bark is used in treatment of diabetes, diarrhoea, liver disease, urinary tract 
disease,constipation and joint pain. 
 
Pharmacological activities of ingredients of Maruthampattai kudineer 
TERMINALIA CHEBULA 
Naik G H et al; observed that aqueous extract of T. chebula was an excellent 
scavenger of DPPH radicals and inhibited xanthine/xanthine oxidase activity. Kannan et 
al;explained thatT. chebula fruit and seeds exhibited dose dependent reduction in blood 
glucose of streptozotocin induced diabetic rats in toxicity studies and also had 
renoprotective activity
. 
Gandhipuram Periasamy Senthilkumar et al; described that the 
ethanolic dry fruit extract showed reduced blood glucose, glycosylated hemoglobin, urea, 
and creatinine as well as fructose, Hexose, hexosamine and sialic acid in the diabetic 
rats.The efficacy of the fruit extract was comparable with glibenclamide, a known 
hypoglycaemic drug
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TERMIALIA ARJUNA 
 
Warrier PK, Nambiar VPet al; has described that the bark has astringent, 
demulcent, expectorant, cardiotonic, styptic, antidysenteric, urinary astringent activity, and 
has shown to be useful in fracture, ulcers, leukorrhea, diabetes, anemia, cardiopathy, and 
cirrhosis.B.Ragavan et al;illustrates that thepresence of tannin, saponin, flavonoids and 
other constituents of T.arjuna bark extract exhibited antidiabetic activity by enhancing the 
peripheral utilization of glucose by correcting the impaired liver and kidney glycolysis and 
by limiting its gluconeogenic formation similar to insulin. Amit Gupta et al;suggests that 
aqueous stem bark extract of Terminalia arjuna and Emblica officinalis showed anti-
diabetic activity with respect to enhancement of granulocytes count and decrease in free 
haemoglobin content including total cellular content in diabetic human.
 
SYZGIUM CUMINI 
Sengupta P et al; portrays that the stem bark is rich in betulinic acid, friedelin, epi-
friedelanol, β-sitosterol, eugenin and fatty acid ester of epi-friedelanolTripathi and Kohli 
et al; studied  the antidiabetic activity of bark extract of Syzygium cumini on streptozotocin 
(STZ)-induced diabetic Wistar albino rats and reported that 30 minutes prior administration 
of Syzygium cumini (L.) extracts before oral glucose loading significantly decreased the rise 
in postprandial blood glucose levels .However the result was less significant than 
glibenclamide. 
ARECHA CATECHU 
Chempakam B et al;has reported  that arecoline a major constituent of Areca 
catechu  have hypoglycemic activity in an animal model of diabetes upon subcutaneous 
administration. The Subcutaneous administration of alkaloid fraction of Areca catechu 
(0.05_/0.5 mg/kg) in alloxanized rabbits (140 mg/kg) showed significant hypoglycemic 
effect lasting for 4/6 hours
. 
Inokuchi J, Okabe H et al describes that Areca tannin inhibits the 
pressure response angiotensin I and II thus showing a regulatory effect on blood pressure. 
FICUS RACEMOSA 
Kar A, Choudhary et al; reports that β-sitosterol isolated from the stem bark was 
found to possess potent hypoglycemic activity when compared to other isolated 
compounds.Jahan IA, Nahar et al explains that  ethanol extract of fruits, exhibited 
significant antioxidant activity in DPPH free radical scavenging assay. 3-O-(E)-Caffeoyl 
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quinate showed significant antioxidant activity. Chopra RN et al ; postulatesthatan infusion 
of bark which  is astringent in nature is employed as mouth wash in spongy gum condition, 
dysentery, menorrhea, hemoptysis, and diabetes.
 
SALACIA RETICULATA 
Matsuda et al; reported the active fraction from S. reticulate shows alpha-
glucosidase inhibitory effect which is the primary activity responsible for its hypoglycaemic 
effect Shimoda et al. demonstrated that an aqueous extract of SR dose dependently 
suppressed the serum glucose level induced by sucrose, maltose and alpha starch but not 
that induced by glucose and lactose.Yoshikawa et al ;explains that the two potent alpha 
glucosidase inhibitors, salacinaol and kotalanol have been identified consistently in studies 
and are believed to be responsible for the attenuation of postprandial glucose in rat models 
as well as humans. 
STRYCHNOS POTATORUM
 
Dhasarathan P, et al., evaluated the anti-diabetic activity in the ethanol extract of the 
plant on blood sugar level, which proved to be effective even at a lower dose (100 mg/kg) in 
decreasing blood sugar level in alloxan treated rats. The plant extract almost brought down 
blood glucose level by 50% in diabetic animals.Ekambaram et al;demonstared that SPP and 
SPE of Strychnos potatorum seeds possess hepatoprotective and antioxidant activities 
against CCl4-induced acute hepatic injury. 
ACACIA NILOTICA: 
Infusion of bark (1½ ounces to one pint of water) is given in chronic diarrhoea and 
diabetes mellitus in doses of 1½ to 2 ounces twice a day
.
The extracts of Acacia nilotica pod 
exhibited strong and effective antioxidant property in vitro and in vivo by chelation to metal 
ions as well as scavenging free radical. It also prevents strand break formation in 
supercoiled plasmid DNA and protein oxidation  
TERMINALIA BELLERICA: 
Ramesh Kumar et al demonstrated that in vitro assessment of the antioxidant activity 
of ethanolic fractions of Terminalia bellerica to scavenge 2, 2- Diphenyl-1-picrylhydrazyl 
(DPPH) and highly reactive hydroxyl radicals showed that the semi pure compounds 
present in the fractions are useful potential source of antioxidants 
..  
M.C.Babu et al; 
demonstrated that administration of T. belerica extract did not have any significant effect on serum 
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glucose level in alloxan diabetic rats during first five days but started reducing from 6
th
 day onwards 
On 9th daywhen compared with that of control diabetic animals serum glucose in extract treated 
animals was found to be reduced to 54% .
 
PHYLLANTHUS EMBLICA: 
 
Priya et al; postulates that the methanolic seed extract of Emblica officinalis has  
promising  free  radical  scavenging  activity  of  1,1, Diphenyl-2-picryl-hydrazil  (DPPH)  
in  a  concentration dependant manner.Jayweera et al; has documented that 
Emblica officinalis is proved as an important inhibitor of Aldose reductase which has its 
involvement in the development of secondary complications of diabetes including cataract.
 
CASSIA AURICULATA 
 
Daisy et al; investigated the effect of Cassia auriculata crude extracts on plasma 
glucose level in normal and experimental rats. STZ-treated diabetic rats showed significant 
increase in the levels of blood glucose when compared to normal rats.a significant elevation 
in the levels of fasting blood glucose, glycosylated haemoglobin (HbA1c), serum insulin, C-
peptide and liver enzyme were observed.Kolar et al; evaluated the antioxidant activity of 
aqueous and ethanol extracts of four plants from the genus Cassia by various antioxidant 
assays, including ferric reducing antioxidant power (FRAP), DPPH free radical scavenging, 
metal chelating activity, phosphor molybdenum reducing power, hydrogen peroxide radical 
scavenging, hydroxyl radical scavenging, deoxyribose degradation and β-carotene bleaching 
assay.  All the extracts showed antioxidant activity in the tested methods. Among the four 
species, Cassia auriculata has been found to possess highest activity in most of the tested 
models 
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MATERIALS AND METHOD 
 
Source of raw drugs: 
The required raw drugs for the preparation of Maruthampattai kudineer were 
procured from the raw drug shop, Parrys, Chennai.  
 
Raw drugs Identification and authentication: 
These ingredients were identified and were authenticated by Dr.D.Aravind M.Sc, 
Asst Prof, Medicinal Botanist at NIS, Tambaram sanatorium, Chennai. 
 
Ingredients: 
 
1. Maruthampattai (Terminalia arjuna) -350 gms 
2. Navalpattai (Syzygium cumini)  -  350 gms 
3. Karuvellampattai (Acacia nilotica)            - 350 gms 
4. Athipattai (Ficus racemosa)               -  350 gms 
5. Avaraithol (Cassia auriculata)   - 350 gms 
6. Kadalalinjilpattai (Salacia reticulata)     - 700 gms 
7. Thetrankottai (Strychnos potatorum)    - 35 gms 
8. Kalipakku (Areca catechu)                   -35 gms 
9. Kadukkai thol (Terminalia chebula)      -35 gms 
10. Nellivatral (Phyllanthus emblica)         - 35 gms 
11. Thandrikai thol (Terminalia bellirica)   - 35 gms 
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RAW DRUGS OF MARUTHAMPATTAI KUDINEER 
 
 
THANDRIKKAI    KARUVELLAM PATTAI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NELLIMULLI      KADALAZHINJILPATTAI 
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MARUTHAMPATTAI                         KADUKKAI 
 
  
 
 
KALIPPAKKU       ATHIPPATAI 
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THETRAN        AVARAIPAATAI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAVAL PATTAI   MARUTHAMPATTAI KUDINEER 
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METHOD OF PURIFICATION & PREPARTION: 
 
Purification methods:  
 Barks General Methods:  
Each bark was cleaned with a clean cotton cloth and dried after removing the 
peel.           Ref. Sigicha Rathana deepam 
 Thaetran vithai(seed) : 
Seeds were soaked in the cow„s milk, then washed and dried. 
Ref .Agathiyar gunavagadam 
 Kalipakku: 
It is boiled and dried. 
Ref .Agathiyar gunavagadam 
  Thandrikkai thol,kadukkai&Nelli mulli: 
The seeds were removed and the remaining part was used. 
Ref .Agathiyar gunavagadam 
 
Preparation:   
 
kUJ lDthiu jhty; tUkj;jpf; fUNtw; gl;il 
jUkJ gyq;fs; gj;J jd;Dld; fye;J $l;b 
tUkJ flypuhQ;rp tUgy kpUgjhf 
gUtpiuNjw;Wf; fspg;ghf;F jpupgiygjf;F 
    ePUof;fha;f; nfhs;Ns. 
- mfj;jpah; 2000 
 
 The above ingredients were ground into coarse powder. 5gm of Marutham pattai 
kudineer powderwas taken and 240 ml of water was added, boiled and reduced to1/4th of 
the part, i.e 60 ml.  
Dosage :  60 ml.bid 
Duration : 90 days 
Reference : AGATHIYAR 2000 part III (pg.no:3) 
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BIOCHEMICAL ANALYSIS 
Biochemical Analysis of Maruthampattai kudineer was done at the Biochemistry lab 
atNational Institute of Siddha, Chennai by the method of Kolkate. 
Preparation of Extract: 
5ml of sample was taken in a 250ml clean beaker and added with 50ml of 
distilledwater. Then it is boiled well for about 10 minutes. Then it was cooled and filtered in 
a 100mlvolumetric flask and made up to 100ml with distilled water. This preparation was 
used forthe qualitative analysis of acidic/basic radicals and biochemical constituents in it. 
Procedure: 
Test for Acid Radicals 
Test for Sulphate: 
2ml of the above prepared extract was taken in a test tube to this added 2ml of 4% 
dilammonium oxalate solution. A cloudy or white precipitate is observed  
Test for chloride: 
2ml of the above prepared extracts was added with 2ml of dil.HCl is added until the 
effervescence ceases off. Cloudy appearance indicates the presence of chloride. 
 
Test for Phosphate: 
2ml of the extract was treated with 2ml of dil.ammonium molybdate solution and 
2ml ofcon.HNo3.Cloudy yellow appearance indicates the presence of phosphate. 
Test for carbonate:  
2ml of the extract was treated with 2ml of dil. magnesium sulphate solution.Cloudy 
appearance indicates the presence of carbonate. 
Test for Nitrate: 
1gm of the extract was heated with copper turning and concentrated H 2 So 4 and 
viewed thetest tube vertically down. Evolution of brown gas indicates the presence of 
nitrate. 
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Test for Basic radicals 
 
Test for lead: 
2ml of the extract was added with 2ml of dil.potassium iodine solution. Yellow 
precipitate indicates the presence of lead. 
Test for copper: 
One pinch (25mg) of extract was made into paste with con. HClin a watch glass 
andintroduced into the non-luminous part of the flame. Blue colour flame indicates the 
presence of copper. 
Test for Aluminium: 
To the 2ml of extract dil.sodium hydroxide was added in 5 drops to excess. No 
characteristic changes indicates its presence 
Test for Iron: 
a. To the 2ml of extract add 2ml of ammonium thiocyanate solution. Appearance of blood 
red colour indicates the presence of iron 
b. To the 2ml of extract 2ml of ammonium thiocyanate solution and 2ml of con HNo3 is 
added.Appearance of blood red colour indicates the presence of iron 
Test for Zinc: 
To 2ml of the extract dil.sodium hydroxide solution was added in 5 drops to excess 
anddil.ammoniumchloride was added. Presence of white precipitate indicates the presence 
of zinc 
Test for Calcium 
To 2ml of the extract was added with 2ml of 4% dil.ammonium oxalate solution. 
Cloudy appearance and white appearance indicates the presence of calcium 
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Test for Magnesium: 
To 2ml of extract dil.sodium hydroxide solution was added in drops to excess. 
White precipitate indicates the presence of magnesium. 
 
Test for Ammonium: 
To 2ml of extract 1 ml of Nessler‟s reagent and excess of dil.sodium hydroxide 
solution were added. Brown colour indicates the presence of ammonium. 
 
Test for Potassium: 
A pinch (25mg) of extract was treated with 2ml of dil.sodium nitrite solution 
andthen treated with 2ml of dil.cobalt nitrate in 30% dil.glacial acetic acid.Yellowish 
precipitate indicates the presence of magnesium. 
 
Test for Sodium: 
2 pinches (50mg) of the extract is made into paste by using HCl and introduced 
intothe blue flame of Bunsen burner.Yellowish flame indicates the presence of sodium. 
 
Test for Mercury: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution.Yellowish 
precipitate indicates the presence of mercury. 
 
Test for Arsenic: 
2ml of the extract was treated with 2ml of dil.sodium hydroxide solution. Brownish 
red precipitate indicates the presence of magnesium. 
 
Test for phytochemicals: 
Test for Starch: 
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2ml of extract was treated with weak dil.Iodine solution. Appearance of blue colour 
confirms its presence. 
 
Test For Reducing Sugar: 
5ml of Benedict‟s qualitative solution was taken in a test tube and allowed to boil 
for 2minutes and added 8 to 10 drops of the extract and again boil it for 2 minutes. The 
colour changes are noted. 
 
Test for the Alkaloids: 
a) 2ml of the extract was treated with 2ml of dil.potassium Iodide solution.The colour 
changes are noted. 
b) 2ml of the extract was treated with 2ml of dil.picric acid.The colour changes are noted. 
c) 2ml of the extract was treated with 2ml of dil.phosphotungstic acid.The colour changes 
are noted. 
 
Test for Tannic Acid: 
2ml of extract was treated with 2ml of dil.ferric chloride solution.black precipitate 
indicates the presence of tannic acid. 
Test for Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium permanganate solution was added.the 
Potassium permanganate solution is not decolourised in the presence of unsaturated 
compound. 
Test for AminoAcid: 
2 drops of the extract was placed on a filter paper and dried well. 20ml of 
Burettereagent is added. Violet colour indicates the presence of amino acid 
 
Test for Type of Compound: 
2ml of the extract was treated with 2 ml of dil.ferric chloride solution. Development  
of green colour indicates the presence of oxyquinalones, pyrocatechol . 
 
PHYSICOCHEMICAL ANALYSIS: 
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Determination of ph range: 
The pH of crude powder in 10 % w/v of water soluble portions of whole plant 
powder was determined using standard simple glass electrode pH meter. 
Determination of moisture content (loss on drying): 
 
This step was done by placing about 1.0 g of whole plant powder, in an accurately 
weighedmoisture disc. For estimation of loss on drying, it was dried at 105ºC for 3hour in 
an oven, cooled in a desiccator for 30 minutes and weighed without delay. The loss of 
weight was calculated as thecontent of in percent of air-dried material. 
 
Determination of total ash: 
 
2 g of air dried coarsely powdered drug was placed in a previously ignited (350ºC 
for 1 hour) and tarred crucible accurately weighed. Dried material was spread in an even 
layer in the crucible and the material ignited bygradually increasing the heat to 550ºC for 5 
hours in a maffle furnaceuntil it is white, indicating the absence ofcarbon. Cooled in a 
desiccator and weighed. Total ash content was calculated in mg per g of air-dried material. 
 
Determination of acid insoluble ash: 
  
The ash was washed from the crucible into 100 ml beaker using25 ml of 2N HCl. It 
was then boiled for 5 min over a Bunsen burner and filtered through an ashless filter paper 
(Whatman No:42). The residue was washed with hot water twice, ignited to ash, cooledin 
desiccators and weighed. The residue was weighed and the acidinsoluble ash of the drug 
was calculated with reference to the air dried sample of crude drug. Acid insoluble ash 
value is frequently necessary to evaluate thecrude drugs. This ash value indicates 
contamination with silicaceous material e.g. earth and sand. The comparisonof this with the 
total ash value of the sample will differentiate between contaminating minerals and 
variations of the natural ash of the drug.  
 
Determination of water soluble extractive value: 
 
Determination of water soluble extractive value is used for evaluating crude drugs 
which are not readily estimated by other means. The extracts obtained by exhausting crude 
drugs are indicative of approximate measure of their chemical constituents. This method is 
applied to drugs which contain water soluble active constituents of crude drugs such as 
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tannins, sugars, plant acids, mucilage and glycosides. The water soluble extractive value can 
be used to indicate poor quality, adulteration with any unwanted material or incorrect 
processing of the crude drug during the process of drying and storage.  
 
About 5 g of powdered plant material was added to 50 ml of water at 80ºC in a 
stoppered flask. It was shaken well and allowed to stand for 10 minutes. It was cooled to 
15ºC, 2g of kieselghur was added into it and filtered. Transferred 5 ml of the filtrate to a 
tarred evaporating basin and evaporated on a water bath and the residue was weighed. The 
percentage of water soluble extractive was calculated with reference to air dried drug.  
 
Determination of alcohol soluble extractive value: 
 
Alcohol is an ideal solvent for extraction of various chemicalslike tannins, resins. 
Therefore this method is frequently employed to determine the approximate resin content of 
drug. Generally 90% ethyl alcohol is used for determination of alcohol soluble extracts. 
Alcohol soluble extracts are one of the tools for standardization of crude drug. Macerated 5 
g of dried coarse powder of plant material with100 ml of 90% ethanol in a closed flask for 
24 h, shaking frequently during 6h and allowing to stand for 18h. It was filtered 
immediately taking precaution against loss of alcohol and 25 ml of filtrate wasevaporated to 
dryness in a tarred flat bottomed shallow dish and dried at 105ºC and weighed. The 
percentage of alcohol soluble extractive was calculated with reference to air dried drug. 
 
PHARMACOLOGICAL STUDIES:  
ANTI DIABETIC ACTIVITY 
In vitro α-amylase inhibitory activity: 
This study was performed by a modified starch iodine protocol. In short, plant 
extract or standard of different concentration (10, 20, 40, 80, 160, 320 µg/mL) was taken in 
prelabeled test tubes. A volume of 20 μL of α-amylase was added to each test tube and 
incubated for 10 min at 37 °C. After the incubation 200 μL of 1% starch solution was added 
to each test tube and the mixture was re-incubated for 1 h at 37 °C. Then 200 μL of 1% 
iodine solution was added to each test tube and after that, 5 mL distilled water was added. 
Absorbance of the mixture was taken at 565 nm. Blank were undertaken under the same 
conditions. IC50 value was calculated by using regression analysis. 
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ANTIOXIDANT ACTIVITY 
Abts radical scavenging assay: 
 
A stock solution of ABTS radical cation was prepared by dissolving ABTS (7 mM, 
25 mL in deionised water) with potassium persulfate (K2S2O8) (140 mM, 440 μL). The 
mixture was left to stand in the dark at room temperature for 15-16 h (the time required for 
formation of the radical) before use. For the evaluation of ABTS radical scavenging 
activity, the working solution was prepared by the previous solution and diluting it in 
ethanol to obtain the absorbency of 0.700 ± 0.02 at 734 nm. The standard and test sample 
(5, 10, 20, 40, 80, 160µg) at different concentrations were mixed with the ABTS working 
solution (1.8 mL) and the reaction mixture was allowed to stand at room temperature for 20 
min, then the absorbance was measured by using a UV-visible spectrophotometer at 734 
nm. The radical scavenging activity is given as ABTS radical scavenging effect that is 
calculated by equation:  
 
ABTS radical scavenging effect (%) = [(A0-A1)/A0] × 100 
 
SAFETY STUDIES: 
The experimental studies on animals were conducted at Animal house, National 
Institute of siddha  
 
 Objective 
The objective of “Acute oral Toxicity Study of Marutham pattai kudineeron 
Female Wistar rats was to measure the toxicological studies of the drug when treated as a 
single dose. Animal should be observed for 14 days after the drug administration. 
Test Guideline Followed: 
Acute toxicity was conducted as per OECD- 423 Guideline with slight modification. 
 
Materials and Methods: 
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The study was conducted on Female wistar rats. These animals were selected 
because of the recommended rodent species for oral studies as per followed guideline 
Female wistar rats, 8-12 weeks old, 140-160gm body weight were used for the study. The 
body weight range should be within ± 20% of the mean body weight at the time of 
Randomization and grouping. The rats were purchased from TANUVAS, Madhavaram, 
Chennai and housed in standard laboratory condition in Polypropylene cages, provided with 
food water adlibitum. 
Acclimatization: 
The animals were selected after veterinary examination by the veterinarian; selected 
rats were kept under acclimatization for a week. 
 
Randomization & grouping: 
After acclimatization, Rats were randomized as control and treated group. Control 
group received distilled water and the treatment group was administered with Marutham 
pattai kudineer 2gms/kg bwt. was a single dose p.o. 
 
Identification: 
Animals were housed with appropriate identification by colouring the fur with picric 
acid solution prepared in water and with cage cards. 
 
Dose Preparation: 
 The dose was prepared of a required concentration before dosing by dissolving, in 
distilled water.  
 
 
Administration: 
The test drugMarutham pattai kudineerwas administered orally to each female 
wistar rats as single dose using a needle fitted on to a disposable syringe of appropriate size. 
 
Observation period: 
After drug administration observations were started to be recorded at the ½ hr, 
1hour, 2hours, 4 hours on day one of dosing and twice daily after that for the next 13 
consecutive days. At the 14th day, sensory reactivity to stimuli of different types was 
conducted. Auditory stimuli responses were measured by clicker sound from approximately 
30 cm to the rats; visual stimuli response were measured with the help of shining pen light 
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in the eye of rats and placing a blunt object near to the eye of rats. Response to 
proprioceptive stimuli was measured by placing anterior/dorsal surface of animals paw to 
the table edge. The responses of reactions for these three exercises were normal in animals 
belonging to both the controls as well as drug treatment dose groups. On day 15, the 
overnight fasted animals (water allowed ad libitum) were sacrificed and examine for gross 
pathological changes in the major internal organs. 
 
Body Weight: 
 Individual weights of animals were determined Marutham pattai kudineerbefore 
administration, weekly thereafter and at 14 days. 
 
Food Consumption: 
 
The quantity of feed was accessible based on the requirement to the group of animal 
housed in each cage (3 rats) and the same was record. The leftover of the feed was 
calculated weekly once. The feed consumed /3 animals /cage /week were calculated by 
subtraction of left over from total quantity of feed offered during that week. 
 
Sacrifice and macroscopic examination: 
 
At the end of study period, the overnight fasted (water ad libitum) animals were 
anaesthetized with ketamine, the animals in control and Marutham pattai kudineertreated 
group were sacrificed on 15th day and gross pathological changes were observed in the 
experimental animals 
 
Statistical analysis: 
 Values are expressed as mean ± SD. Statistical significance (p) calculated by one 
way ANOVA followed by dunnett‟ s. P< 0.05 considered as significant by comparing 
treated group with control group using Graph Pad Prism 3. 
 
REPEATED DOSE 90-DAYS ORAL TOXICITY STUDY: 
 Objective: 
Repeated dose 90-days oral toxicity studywas conducted as per OECD-408 
Guideline. Animals should be observed for 90 days during theMarutham pattai 
kudineeradministration. The 90 days study provides information on the possible health 
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hazard likely to raise from repeated exposure over a prolonged period of time covering post-
weaning maturation and growth well into adulthood. 
 
MATERIALS AND METHODS 
 
Test System Detail 
Young adult wistar rats of 8-12 weeks old weighing 140-160 gms of both the sex 
was used for study. The body weight range should be within ± 20% of the mean body 
weight at the time of Randomization and grouping. Animals were housed in four groups 
(5/cage/sex) in polypropylene cages in a well-ventilated room under a temperature of 22 ± 
3°C and 30 - 70% relative humidity, with a 12-hr light/dark artificial light cycle. The rats 
were purchased from TANUVAS, Madhavaram, Chennai and housed in standard laboratory 
condition in Polypropylene cages, provided with food water adlibitum 
 
Acclimatization 
 The animals were selected after veterinary examination by the veterinarian. All the 
selected animals were kept under acclimatization for a week. 
 
Randomization & grouping: 
One day before the initiation of treatment (last day of acclimatization), the selected 
animals were randomly grouped into six different groups containing 10 male animals and 
10 female animals per group. 
 
Numbering and Identification: 
Animals were housed with appropriate identification by colouring the fur with picric 
acid solution prepared in water and with cage cards. The group no., cage no., sex of the 
animal and animal no. were identified as indicated below using cage label and body 
marking on the animals 
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Numbering and Identification of animals in repeated dose 90-days oral toxicity study 
       
CAGE NO GROUP NO ANIMAL SEX 
1 I 
CONTROL 
1-10 
10-20 
MALE 
FEMALE 
2 II 
LOWDOSE 
21-30 
31-40 
MALE 
FEMALE 
3 III 
MID DOSE 
41-50 
51-60 
MALE 
FEMALE 
4 IV 
HIGH DOSE 
61-70 
71-80 
MALE 
FEMALE 
 
Dose level repeated dose 90-days oral toxicity study: 
 
TEST GROUP DOSE TO ANIMALS 
(mg/ kg.b.wt) 
NO.OF ANIMALS 
GROUP I Control distilled 
water(10ml/kg.b.wt) 
20 (10male and 10female) 
GROUP II 900mg /kg.bwt 20 (10male and 10female) 
GROUP III 1800 mg /kg.bwt 20 (10male and 10female) 
GROUP IV 3600 mg /kg.bwt 20 (10male and 10female) 
 
Dose Preparation: 
 Marutham pattai kudineerwas prepared at the calculated dose of a required 
concentration. 
 
Administration:  
The test drug was administered orally to each rat as single dose using a needle fitted 
onto a disposable syringe of appropriate size at the following different doses. The 
concentration was adjusted according to its body weight; the volume not exceeding 10 
ml/kg body weight. Variability in test volume was minimized by adjusting the concentration 
to make sure a constant volume at all dose levels. 
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 Observations:  
The observations included but were not restricted to changes in skin and the eyes 
and mucous membranes and in the respiratory, circulatory, central and autonomous nervous 
systems and behaviour. 
 
Clinical signs of toxicity:  
All the rats were observed at least two times daily with the purpose of recording any 
symptoms of ill- health or behavioural changes and clinical signs of toxicity daily for 90 
days. 
 
Food and water intake:  
A measured amount of feed was kept in the cages and then after 24 hrs. the left out 
amount of feed was measured to calculate the amount of food consumed by the rats. 
 Water intake was observed by visual observation during the Study. In addition, the water 
consumption in each cage was observed daily for a period of 90 days  
 
Body weight:  
The body weight of rats were recorded one week before the start of treatment, and 
during the course of the treatment on day one, 7
th
, 14
th
, 21
st
, 28
th
,35
th
 ,42
nd
,49
th
,56
th
, 63rd 
70
th
, 77
th
,84
th
, 90
th
day (day of sacrifice)  
 
Pre-terminal deaths: 
 All rats were observed twice daily for any pre terminal deaths. 
 
Blood Collection:  
Blood was collected through retro-orbital sinus from all the animals of four groups 
on 90th day. The blood was collected in tubes containing as an anticoagulant 
(Heparin/EDTA). Animals were fasted overnight prior to the blood collection. 
 
 Laboratory studies:  
 
During the last day of treatment, blood were withdrawn from the orbital sinus of 
animals from each group, under thiopental sodium anaesthesia. The collected blood samples 
also centrifuged 10000 rpm in 10 minutes to separate the serum. The separated serum used 
to evaluate biochemical parameters like SGOT, SGPT, ALP and BILIRUBIN etc. The 
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following hematological parameters were analysed (Autoanalyser) Haemoglobin (g %)  
Packed Cell Volume, White Blood Corpuscles (x103/cmm), Red Blood Corpuscles 
(x106/cmm) Blood Platelet count (x103/cmm) Differential WBC count. 
 
The following clinical Bio parameters were analysed using Auto analyser. Total 
serum protein (g/dl), Alanine amino transferase (U/L), Aspartate amino transferase (U/L) 
Alkaline serum phosphatase (U/L), Cholesterol (mg/dL) Triglyceride 
 
Sacrifice and macroscopic examination: 
 
At the end of study period, the overnight fasted animals were anaesthetized with 
thiopental sodium and blood samples were collected from retro-orbital sinus. After blood 
collection, the animals in group 1 to 4 were sacrificed on 90th day.  
 
Histopathology:  
 
The target organs from control and drug treated animals were preserved in 10 % 
buffered neutral formalin for histopathological examination. Control and highest dose 
animals will be initially subjected to histopathological investigation. If any abnormality was 
found in the highest dose group, then the low and mid group will also be examined. All 
deviations from normal histology were recorded and compared with corresponding controls. 
 
Statistical analysis:  
 
Values are expressed as mean ± SDStatistical significance (p) calculated by one way 
ANOVA followed by dunnett‟ s. P< 0.05 considered as significant by comparing treated 
group with control groupusing Graph Pad Prism 3.0 
 
CLINICAL STUDY: 
Clinical trial Approval & Registration: 
The Clinical trial was approved by the Institutional Ethics Committee (IEC) of National 
Institute of Siddha, Chennai 47 (NIS/IEC/2016/11-09 Date. 14.10.2016) and further registered in 
Clinical Trial Registry of India (REG NO.CTRI/2018/04/013163) 
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Study Centre: 
 Clinical study was conducted at Ayothidoss Pandithar Siddha Hospital, National Institute of 
Siddha (NIS), Tambaram Sanatorium, Chennai - 47. Necessary permission was obtained from the 
Administrative head to conduct the study. 
 
SUBJECT SELECTION: 
 As and when patients with symptoms of inclusion criteria reporting at OPD 
Aythidoss pandithar hospital of NIS will be subjected to screening test & documentation 
will be done using screening proforma. 
 
INCLUSION CRITERIA 
 Age : 35-65 years 
 Sex : Both Males and Females 
 
With symptoms of 
 Polyuria 
 Polydipsia 
 Nocturia 
 Polyphagia 
 Blood glucose level: 
 Fasting plasma blood glucose level-≤ 150 mg/dl 
 Two Hours postprandial plasma blood glucose level- ≤250 mg/dl 
 Glycosylated haemoglobin (HbA1c)  ≤ 8% 
 Non-Insulin Dependent Diabetes Mellitus 
 Patient willing to give blood and urine sample before and after the treatment 
 Willing to participate in Study and signing consent by fulfilling the condition of 
Proforma. 
 
EXCLUSION CRITERIA 
 Fasting plasma blood glucose level- >151 mg/dl 
 2 Hours postprandial plasma blood glucose level- >251 mg/dl 
 Glycosylated haemoglobin (HbA1c)- > 8.1% 
 Patient with diabetic complications diabetic foot, retinopathy etc., 
 Insulin Dependent Diabetes Mellitus 
 Any other serious Systemic Diseases 
 Pregnancy and lactation 
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WITHDRAWL CRITERIA 
 Reluctant to continue the study 
 Poor patient compliance &defaulters 
 Increase in severity of symptoms 
 
TEST & ASSESSMENTS  
1. CLINICAL ASSESSMENT  
2. SIDDHA ASSESSMENT 
3. ROUTINE INVESTIGATION 
4. SPECIFIC INVESTIGATION   
1. CLINICAL ASSESSMENT              
 Increased frequency of Urination (polyuria)  
 Thirst (polydipsia) 
 Excessive hunger (polyphagia) 
 Body pain  Tiredness   
 Burning feet    
 Generalized/genital pruritis  
 
2. SIIDDHA ASSESSMENT 
Enn Vagai Thervu (Eight types of Examination):  
1. Nadi (Pulse perception) 
 2. Naa (Tongue) 
 3. Niram (Complexion) 
 4.  Mozhi (Voice)  
 5. Vizhi (Eyes)  
6. Parisam (Palpatory perception) 
 7. Malam (Bowel habits)  
8. Moothiram (Urine){Neerkuri& Neikuri}   
 
3. ROUTINE INVESTIGATION HAEMATOLOGY  
 Hb (gms%) 
 Total WBC Count(cells/cumm) 
 DC 
Polymorphs(%) 
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Lymphocytes (%) 
Eosinophils (%)    
Monocytes (%) 
Basophils (%) 
 Total RBC count (cells/cu.mm)  
 ESR(mm/hr)  
 
CLINICAL BIOCHEMISTRY   
RENAL FUNCTION TEST 
 Blood urea (mg/dl) 
 S. total creatinine (mg/dl) 
 Uric acid (mg/dl)   
 
LIPID PROFILE  
 S. Total cholesterol (mg/dl) 
 HDL (mg/dl) ,sLDL  (mg/dl) ,VLDL (mg/dl) ,TGL (mg/dl)   
 
LIVER FUNCTION TEST  
 S. Total bilirubin (mg/dl) 
 S. Direct bilirubin (mg/dl)  
 S. Indirect bilirubin (mg/dl)   
 SGOT (U/dl) 
 SGPT (U/dl)  
 S. Alkaline phosphatase (U/dl)   
 
URINE EXAMINATION  
  Neerkuri and Neikuri 
  Albumin   
  Sugar (Fasting & postprandial) 
  Deposits    
4. SPECIFIC INVESTIGATION  
HbA1C (> 6)  
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ENROLLMENT OF THE PATIENTS: 
 
In this clinical trial, patients reporting at NIS OPD with the clinical symptoms of 
Polyuria, Polydipsia, Polyphagia, General body pain and tiredness were examined clinically 
for enrolling in the study based on the inclusion and exclusion criteria.  The enrolled 
patients were informed about the study, trial drug, possible outcomes and the objectives of 
the study in the language and terms understandable to them and getting consent in the 
Informed consent form.  
 
All the patients were given unique registration card in which there would be 
patient‟s registration number of the study, Address, Phone number and Doctors phone 
number etc. so as to report easily whenever any complication arises. Complete clinical 
history, complaints and duration, examination findings were recorded in the prescribed 
Proforma.Patients were advised to take the trial drug and appropriate dietary advice. 
 
CONDUCT OF THE STUDY: 
 
The trial drug “Maruthampattai kudineer” was given for 90 days. OPD patients were 
requested to visit the hospital once in 7 days. In each and every visit clinical assessment and 
prognosis were recorded. Laboratory investigations were done on the first day and also at 
the end of the trial. Defaulters for more than three days would not be allowed to continue 
and would be withdrawn from the study with fresh cases being inducted. OP Patients were 
requested to visit the hospital once in 7 days.At each visit clinical assessment was done and 
prognosis noted. The Laboratory Investigation was done on the 0 day and 91
st
 day of the 
trial. At the end of the treatment, the patients were advised to visit the OPD for further 3 
months for follow-up. Patients were advised to practice asanas in empty stomach after 
evacuation of urine and motion for 45-60 minutes every morning. Asanas were taught to the 
patients during their each visit to the OPD. Under my guidance, the patients were asked to 
do the recommended pattern of asanams at NIS  yogam hall on their each visit . Patients 
were motivated to practise asanas regularly for their well-being even after the study. 
 
If any trial patient who fails to collect  the trial drug on the prescribed day but wants to 
continue in the trial from the next day or two, he/she will be allowed, but defaulters of one week and 
more will not be  allowed to continue and be withdrawn from the study with fresh case being 
inducted.   
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ADVERSE/SERIOUS EFFECTS MANAGEMENT: 
 
If the study patient develops any inconveniences, he/she was immediately 
withdrawn from the study. It will also be reported to the Institutional Ethical Committee 
member of NIS.  
 
OUTCOME 
 
 The changes in plasma blood glucose level by using Blood Investigations before and after 
the treatment were observed 
1. Fasting blood glucose level 
2. Postprandial blood glucose level 
3. HbA1C   
 
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, only disposable 
syringes, disposable gloves, with proper sterilization of lab equipment‟s were used. 
2. The data collected from the patient is kept confidently. The patient was informed about 
the diagnosis, treatment and follow- up. 
3. After the consent of the patient (through consent form) they were enrolled in the study. 
4. Informed consent was obtained from the patient explaining in the understandable to the 
patient. 
 
DATA COLLECTION FORMS: 
 FORM l Screening & selection proforma 
 FORM lI  Case record form 
 FORM llI Laboratory parameters chart 
 FORM lV Drug compliance form 
 FORM  V Information sheet 
 FORM VI Consent form 
 FORM VII Withdrawal form/ adverse drugReaction/ pharmacovigilance form  
 FORM VIII Dietary advice form 
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Authentication of the ingredients: 
The herbal ingredients of Maruthampattai kudineer were identified and 
authenticated by the Medicinal Botanist of NIS (certificate number: NISMB2902017). 
 
Purification of ingredients: 
The raw drugs were purified as per the methods mentioned in the Siddha literatures. 
After purification, the ingredients are dried in the shade. 
 
Preparation of Maruthampattai kudineer: 
The raw drugs are made into a coarse powder.  
 
 RESULTS OF BIOCHEMICAL ANALYSIS: 
Results of Acid radicals studies 
 
S.NO Parameter Observation Result 
1 Test for Sulphate Cloudy appearance 
Present 
Positive 
2 Test for Chloride - Negative 
3 Test For Phosphate Cloudy yellow 
appearance present 
Positive 
4 Test For Carbonate   Cloudy appearance 
Present 
Positive 
5 Test For Nitrate - Negative 
6 Test for Sulphide - Negative 
7 Test For Fluoride &oxalate - Negative 
8 Test For Nitrite - Negative 
9 Test For Borax - Negative 
 
Interpretation 
The acidic radicals test shows the presence of Sulphate, phosphate, carbonate. 
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Results of basic radicals studies: 
S.NO Parameter Observation Result 
1 Test for Lead - Negative 
2 Test for Copper - Negative 
3 Test For Aluminium. - Negative 
 Test For Iron. - Negative 
5 Test For Zinc - Negative 
6 Test for Calcium Cloudy appearance and 
white precipitate  present 
Positive 
7 Test For Magnesium - Negative 
8 Test For Ammonium - Negative 
9 Test For Potassium 
 
- Negative 
10 Test For Sodium - Negative 
11 Test For Mercury - Negative 
12 Test For Arsenic - Negative 
 
Interpretation 
The basic radical test shows the presence of Calciumand absence of heavy metals such as 
Lead, Iron, Arsenic and Mercury. 
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Test for phytochemicals: 
S.NO Parameter Observation Result 
1 Test for Starch  
- 
Negative 
2 Test for Reducing sugars 
 
- Negative 
3 Test For Alkaloids 
 
Yellow colour developed Positive 
4 Test For Tannic acid 
. 
Blue-black precipitate 
obtained 
Positive 
5 Test for unsaturated 
compounds 
- Negative 
6 Test for Amino acid - Negative 
7 Test For Type of compounds 
 
Green  colour developed Oxyquinalone, 
epinephrine and pyro 
catechol 
 
Interpretation 
The Miscellaneous test shows the presence of Alkaloids, Tannic acid, 
Oxyquinalone,epinephrine and pyro catechol 
 
RESULTS OF PHSICOCHEMICAL ANALYSIS 
Organoleptic characters: 
Colour  :  Brown. 
Odour  : Pleasant.  
Taste  : Astringent.  
Consistency : Coarse powder 
S.No Physicochemical analysis Results (w/w) 
1.  Description Brownish powder 
2.  pH (10 % w/v aq. solution) 4.96 
3.  Loss on drying at 105°C 11.58 % 
4.  Total ash 16.74 % 
5.  Acid-insoluble ash 0.98 % 
6.  Water-soluble extractive 24.29 % 
7.  Alcohol soluble extractive 18.96 % 
 
This formulation satisfy the Pharmacopoeia standards and as per the WHO Guidelines. 
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PHARMACOLOGICAL ACTIVITY: 
Anti-diabetic activity: 
The finding of inhibitory activity of Maruthampattai kudineer is represented in the 
below table. The IC50 value was 160.017μg/ml for on α-amylase enzyme.The standard drug 
Acarbose exhibited 50% inhibition on α-amylase enzyme at 58.26 μg/ml. 
S.NO CONC. MP ACARBOSE 
1 50 27.5147929 24.84662577 
2 100 32.87671233 28.98550725 
3 250 69.14357683 58.26235094 
4 500 77.56410256 71.14252061 
5 1000 83.17307692 77.9676259 
6 2000 84.20373952 81.68908819 
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Antioxidant activity: 
ABTS assay 
The IC50 value of Maruthampattai kudineer (MP) was 12.02 and the standard drug 
(Ascorbic acid) was 7.53 
CONC. MP ASCORBIC ACID 
5µg 14.9 24.33 
10µg 39.27 52.21 
20µg 85.75 96.61 
40µg 91.5 97.3 
80µg 94.8 98.6 
160µg 97.4 99.1 
 
 
 
TOXICITY STUDY 
Acute toxicity 
                  Maruthampattai kudineerwas administered single time at the dose of 2gms/kg 
to rats and observed for consecutive 14 days after administration. According to the OECD 
guideline 423 when there is information in support of non-toxicity or low and immortality 
nature of the test substance, then the limit test at the dose level 2 gms/kg body weights 
(highest starting dose level) was conducted. All animals were observed daily once for any 
abnormal clinical signs. Weekly body weight and food consumption were recorded. 
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83 
 
 No mortality was observed during the total period of the study. Data obtained in this study 
indicated no significance physical and behavioural signs of any toxicity due to 
administration of Maruthampattai kudineerat the dose of 2gms/kg to rats. At the 14th day, 
all animals were observed for functional and behavioural examination.  
In functional and behavioural examination, home cage activity, hand held activity 
were observed. Home cage activities like Body position, Respiration, involuntary 
movement, (Clonic and Tonic), Palpebral closure, Approach response, Touch response, 
Pinna reflex, Sound responses, Tail pinch response were observed. Handheld activities 
(Reactivity and Handling), Palpebral closure, Lacrimation, Salivation, Piloercetion, 
Papillary reflex, abdominal tone, Limb tone were observed. Functional and behavioural 
examination was normal in all groups. Food consumption of all treated animals was found 
normal as compared to control group. Body weight at weekly interval was measured to find 
out the effect of Marutham pattai kudineeron the growth rate. No significant body weight 
changes were observed between control and treatment group. There were no treatment 
related mortality in both control and treatment groups throughout the experimental period 
No pathological (gross) changes were observed in the experimental animals  
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Effect of Maruthampattai kudineeron Body weight of Wistar Rats in acute 
toxicitystudy 
TREATMENT 
BODY WEIGHT 
DAY 1 DAY 7 DAY 14 
CONTROL 144±.27 154.5±0.45 162.7±0.64 
MP 
(2000mg/kg) 
149±0.32 153±0.17 160±0.75 
 
Values are expressed as mean ± SD. Statistical significance (p) calculated by one 
way ANOVA followed by dunnett‟s. P< 0.05 considered as significant by comparing 
treated group with control group using Graph Pad Prism. 
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Clinical Observation of control and Maruthampattai kudineertreated 
experimentalanimals in acute toxicity study 
OBSERVATION SIGNS OBSERVATION SIGNS 
Lethality    X Stereotypies(chewing)    X 
Convulsion    X Stereotypies 
(Head movements) 
   X 
Tremor    X Head twitches    X 
 Straub tail    X Scratching    X 
Sedation 
 
#1    X Respiration    X 
#2    X Aggressiveness    X 
#3    X Fear    X 
Excitation #1    X Reactivity to touch     X 
#2    X Muscle tone    X 
 #3    X Loss of rightingReflex    X 
Abnormal gait(rolling) X Ptosis  X 
Abnormal gait(tip toe) X Exophthalmos X 
Jumps  X Loss of grasping X 
Motor coordination X Akinesia X 
Loss of balance X Catalepsy X 
Fore paw treading X Loss of traction X 
Writhes X Loss of corneal reflex X 
Piloerection X Analgesia X 
Salivation X Defecation X 
Lacrimation X Others X 
X – No sign / √ - Present; Values are expressed as mean ± SD      
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Gross pathology observations of control and Marutham pattai kudineertreated 
experimental animals 
ORGANS OBSERVATION 
Brain  No abnormal lesion observed 
Eyes No abnormal lesion observed 
Lymph node No abnormal lesion observed 
Trachea No abnormal lesion observed 
Oesophagus No abnormal lesion observed 
Lungs No abnormal lesion observed 
Heart No abnormal lesion observed 
Brain No abnormal lesion observed 
Liver  No abnormal lesion observed 
Stomach No abnormal lesion observed 
Duodenum No abnormal lesion observed 
Small and large intestine No abnormal lesion observed 
Kidney No abnormal lesion observed 
Spleen No abnormal lesion observed 
Sex organs No abnormal lesion observed 
Pancreas No abnormal lesion observed 
 
REPEATED DOSE 90-DAYS ORAL TOXICITY STUDY 
 
Clinical Signs  
No abnormal home cage activities, behavioural responses or neurological symptoms 
were observed before and after the exposure of Maruthampattai kudineeer. All animals in 
this study were free of toxic clinical signs throughout the dosing period of 90 days. 
Mortality: 
Since examination of clinical signs plays main role in toxicological testing, mortality 
and morbidity were recorded two times a day throughout the study. All animals in control 
and in all the treated dose groups survived during the dosing period of 90 days. 
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Body weight: 
Results of body weight determination of animals from control and different dose 
groups exhibited comparable body weight gain (throughout the dosing period of 90 days)  
 
Food and water consumption: 
Feed and water consumption of Maruthampattai kudineertreated groups were found 
to be in significant in both the sexes when compared to control. The faecal/urinary excretion 
patterns were also found to be normal in MP administered rats in comparison to the vehicle 
treated rats.  
Clinical Observation of control and Maruthampattai kudineertreated 
experimentalanimals in repeated dose 90-days oral toxicity study 
 
OBSERVATION SIGNS OBSERVATION SIGNS 
Lethality X Stereotypies(chewing) X 
Convulsion X Stereotypies 
(Head movements) 
X 
Tremor X Head twitches X 
Straub tail X Scratching X 
Sedation 
 
#1 X Respiration X 
#2 X Aggressiveness X 
#3 X Fear X 
Excitation #1 X Reactivity to touch X 
#2 X Muscle tone X 
 #3 X Loss of rightingReflex X 
Abnormal gait(rolling) X Ptosis X 
Abnormal gait(tip toe) X Exophthalmos X 
Jumps X Loss of grasping X 
Motor coordination X Akinesia X 
Loss of balance X Catalepsy X 
Fore paw treading X Loss of traction X 
Writhes X Loss of corneal reflex X 
Piloerection X Analgesia X 
Salivation X Defecation X 
Lacrimation X Others X 
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Effect of Maruthampattai kudineeron Body weight of experimental 
Wistar rats in 90 days repeated oral toxicity study 
 
SL.NO            DAY     CONTROL LOW DOSE MID DOSE HIGH DOS 
1. Initial day 150.9± 6.57 151.5 ± 5.19 153.8 ±5.88 154.5  ± 4.83 
2. 15
th
day 162.6± 6.63 164.1 ± 6.31 166.9  ± 8.10 168.4  ±  6 
3. 30
th
day 174.5 ±  6.91 177.2± 6.35 178.2 ± 9.95 180.5 ± 6.81 
4. 45
th
day 186.5± 7.30 188.9± 6.80 188.7  ± 11.70 192.9  ± 7.60 
5. 60
th
day 199.1± 8.71 201.9 ± 7.59 204.2 ± 13.02 206.6 ±8.01 
6. 75
th
day 212.3± 10.14 214.9± 8.39 216.8 ± 14.06 220  ± 9.11 
7. 90
th
day 225.4± 11.39 230.1 ± 9.26 229 ± 15.43 235.9 ±10.53 
 
Values are expressed as mean ± SD. Statistical significance (p) calculated by one 
way ANOVA followed by dunnett‟s. P< 0.05 considered as significant by comparing 
treated group with control group using Graph Pad Prism 
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Hematological Investigations: 
The haemopoietic system serves as vital goal for toxic chemicals and is a susceptible 
index for pathological conditions both in humans and animals. The results of 
haematological investigations conducted on day 90 does not reveal any significant changes 
in the values of various parameters observed when compared with those of respective 
control. 
Effect of Maruthampattai kudineer of haematological parameters of 
experimentalWistar rats in 90 days repeated oral toxicity study. 
 
BLOOD 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
RBC 
 
5.66±0.34 6.85±0.69 6.24±0.55 6.61±1.11 
WBC 
 
9.07±2.17 9.26±2.18 9.38±2.11 8.30±1.5 
PLATLET 
 
769.75±80.65 726.6±126.17 626.6±91.55 757.55±110.6 
HB 12.12±1.7 12.81±1.63 12.56±1.59 12.85±1.38 
 
T.CHOLESTEROL 
 
108.92±13.4 113.55±18.43 132.54±9.81 129.74±12.86 
TGL 
 
49.35±5.1 40.25±7.9 40.65±8.06 38.5±10.88 
CREATININE 
 
0.58±0.19 0.72±0.16 0.69±0.21 0.68±0.21 
SGOT 
 
88.2±7.14 90.35±20.5 92.15±23.30 95.45±16.28 
SGPT 
 
28.85±7.43 30.85±8.02 37±9.13 32.35±8.96 
T.BILIRUBIN 
 
0.35±0.16 0.51±0.36 0.44±0.25 0.93±1.08 
 
90 
 
 
 
 
 
  
0
1
2
3
4
5
6
7
5.66
6.84
6.24
6.61
RBC
0
100
200
300
400
500
600
700
800
769.5
726
626.5
757.5
PLATELET
7.6
7.8
8
8.2
8.4
8.6
8.8
9
9.2
9.4
9.07
9.26
9.38
8.3
WBC
11.9
12
12.1
12.2
12.3
12.4
12.5
12.6
12.7
12.8
12.9
12.24
12.81
12.56
12.8
HAEMOGLOBIN
91 
 
 
 
 
 
 
 
  
0
20
40
60
80
100
120
140
113.5
131.5 129.7
108.9
TOTAL CHOLESTROL
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.58
0.72
0.69 0.68
CREATININE
0
5
10
15
20
25
30
35
40
45
50
40 40.6 38.5
49.2
TGL
84
86
88
90
92
94
96
88.2
90.35
92.1
95.47
SGOT
92 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
Control 900mg/kg 1800mg/kg 3600mg/kg
28.6
30.85
37
32.35
SGPT
0
0.1
0.2
0.3
0.4
0.5
0.6
Control 900mg/kg 1800mg/kg 3600mg/kg
0.35
0.51
0.44
0.35
T.BILURUBIN
93 
 
CONTROL MALE 
Histopathology of Heart 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Lung 
 
Low Power Magnification 10X               High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
94 
 
Histopathology of Liver 
 
Low Power Magnification 10X         High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Kidney 
 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Spleen 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Testes 
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CONTROL FEMALE 
Histopathology of Heart 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Lung 
 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Stomach 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
  
 
 
 
 
 
 
 
 
Histopathology of Liver 
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Histopathology of Kidney 
 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
Histopathology of Spleen 
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Histopathology of Uterus 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Ovary 
 
Low Power Magnification 10X   High Power Magnification 40X 
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HIGH DOSE- MALE 
Histopathology of Brain 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Heart 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Lung 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Stomach 
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Histopathology of Liver 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
Histopathology of Kidney 
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Histopathology of Spleen 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Testes 
 
Low Power Magnification 10X   High Power Magnification 40X 
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HIGH DOSE – FEMALE 
Histopathology of Brain 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
  
 
 
 
 
 
 
 
 
 
 
Histopathology of Heart 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Lung 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Stomach 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Liver 
 
Low Power Magnification 10X   High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
Histopathology of Kidney 
Low Power Magnification 10X   High Power Magnification 40X 
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Histopathology of Spleen 
 
Low Power Magnification 10X  High Power Magnification 40X 
 
 
 
 
 
 
 
 
 
 
 
Histopathology of Uterus 
 
Low Power Magnification 10X  High Power Magnification 40X 
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Histopathology of Ovary 
 
Low Power Magnification 10X   High Power Magnification 40X 
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CLINICAL STUDY 
95 subjects were screened for diabetes at National Institute of Siddha. Subjects those 
fulfilled the inclusion criteria were recruited after obtaining informed consent. Totally 44 
numbers of individuals of both genders were recruited in this study. 4 patients had 
withdrawn from the study. 40 patients had completed the entire course of trial period.  
Number of patients screened for eligibility: 95 
Number of patients included in trial: 44 
Number of patients withdrawn from the trial: 4 
 Number of patients who reported adverse drug reactions: 0  
Duration of trial: 90 days (treatment period) 
The observation and results were studied and tabulated under the following heading. 
 Sex distribution 
 Age distribution 
 Religion   
 Occupational status 
 Socio economic status 
 Family History 
 Personal habits 
 Dietary habits 
 Thinai distribution 
 Gunam distribution 
 Kaalam distribution (According to Age) 
 Paruva Kaalam 
 UdarKattukkal reference 
 Distributions of three thodams 
 En Vagaithervugal 
 Clinical features  
 Chronicity of illness  
 Result 
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GENDER DISTRIBUTION: 
 
S.NO SEX NO.OF CASES PERCENTAGE 
1 Male 26 65% 
2 Female 14 35% 
 
 
  
 
Observation: 
Among the 40 patients selected for this study, 65% were males and 35% females. 
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DISTRIBUTION OF AGE INTERVAL: 
 
S.NO AGE INTERVAL NO.OF CASES PERCENTAGE 
1 35-45 10 25% 
2 45-55 15 37.5% 
3 55-65 15 37.5% 
  
 
 
 
Observation: 
Age group 35-45 were 25% (10cases), age group 45-55 were 37.5% (15 cases), and 
age group 55-65 were 37.5% (15 cases). 
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90%
2.5%
7.5%
RELIGION
HINDU
MUSLIM
CHRISTIAN
RELIGION: 
 
 
 
    
 
 
Observation: 
                Out of 40 cases 90% of patients (36) were Hindu, 2.5% (1) patients wasMuslim, 
and 7.5% of patients (3) were Christian. 
 
 
 
 
 
S.NO RELIGION NO.OF CASES PERCENTAGE 
1 Hindu 36 90% 
2 Muslim 1 2.5% 
3 Christian 3 7.5% 
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OCCUPATIONAL STATUS: 
 
S.NO OCCUPATION NO.OF 
CASES 
PERCENTAGE 
1 Driver 3 7.5% 
2 Carpenter 2 5% 
3 Shopkeeper 1 2.5% 
4 Manual worker 20 50% 
5 Nurse 1 2.5% 
6 House wife 11 27.5% 
7 Business man 1 2.5% 
8 Security guard 1 2.5% 
   
 
Observation: 
 Out of 40 cases 7.5% of patients (3) were Drivers, 5% (2) patients were 
Carpenter, 2.5% (1) case was shop keeper, 50% of patients (20) were manual workers, 
27.5% of patients (11) were house wives, 2.5% (1) case was nurse, 2.5% (1) case was 
business man and 2.5% (1) case was security. 
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SOCIO ECONOMIC STATUS 
S.NO SOCIO ECONOMIC STATUS NO.OF CASES PERCENTAGE 
1 Poor 8 20% 
2 Middle 26 65% 
3 Rich 6 15% 
 
 
Observation: 
 Among 40 patients 20% of cases (8) were under poor socio- economic status and 
65%of cases (26) were from middle class family and 15% of cases (6) were rich. 
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FAMILY HISTORY 
S.NO FAMILY HISTORY NO.OF 
CASES 
PERCENTAGE 
1 Present 27 67.5% 
2 Absent 13 32.5% 
  
 
 
 
 
 
Observation: 
 Out of 40 Patients 27 cases (67.5%) had positive family history of type 2 
diabetes, reveals genetic predisposition of the disease. 
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PERSONAL HABITS: 
 
S.NO PERSONAL HABITS NO.OF CASES PERCENTAGE 
1 Smoker 9 22.5% 
2 Alcoholic 11 27.5% 
3 Non Smoker / Non Alcoholic 20 50% 
 
 
 
 
 
 Observation  
Out of 40 cases 22.5% of patients (9) were smokers, 27.5 % (11) patients were alcoholic, and 50% 
(20) cases were Non-smokers & Non Alcoholic. Irrespective of personal habits the disease affects 
all groups such as smokers, alcoholic, non-smokers & non alcoholic 
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DIETARY HABITS 
 
S.NO DIET NO.OF CASES PERCENTAGE 
1 Vegetarian 4 10% 
2 Non vegetarian 36 90% 
 
 
 
 
Observation: 
Non vegetarian (90%) are more prone tomadhumegam than vegetarians. 
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THINAI DISTRIBUTION: 
 
S.NO THINAI NO.OF CASES PERCENTAGE 
1 Kurinji - - 
2 Mullai - - 
3 Marutham 10 90% 
4 Neithal 36 10% 
5 Paalai - - 
 
 
 
 
 
Observation: 
Out of 40 cases 10% of patients (4 cases) were from Marutham thinai and 90% (36 
cases) were from Neithal thinai. 
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GUNAM:  
 
S.NO GUNAM NO.OF CASES PERCENTAGE 
1 Sathuvam 0 0 
2 Raso 40 100% 
3 Thamo 0 0 
 
 
 
Observation: 
Out of 40 cases all patients had raso gunam. 
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KAALAM DISTRIBUTION: 
 
S.NO KAALAM NO.OF CASES PERCENTAGE 
1 Vatham(1-33 years) 0 0 
2 Pitham(34-66 years) 40 100% 
3 Kabam(67-99 years) 0 0 
 
 
 
 
 
Observation: 
All the patients included for the study were from pitha kalam (34-66 years) 
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PARUVA KAALAM: 
 
S.NO PARUVA KAALAM NO.OF CASES PERCENTAGE 
1 Kar kaalam 0 0 
2 Koothir kaalam 0 0 
3 Munpani kaalam 19 47.5% 
4 Pinpani kaalam 21 52.5% 
5 Ilavenir kaalam 0 0 
6 Muthuvenir kaalam 0 0 
 
 
 
Observation: 
Out of 40 cases 47.5% of patients (19 cases) were included in Munpanikalam, 
52.5% (21cases) patients were in Pinpani kalam. 
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UDAL THATHUKKAL: 
 
S.NO UDAL THATHUKKAL NO.OF CASES PERCENTAGE 
1 Saram 40 100% 
2 Cheneer 40 100% 
3 Oon 2 5% 
4 Kozhuppu 2 5% 
5 Enbu 0 0 
6 Moolai 0 0 
7 Sukkilam 2 5% 
 
 
 
 
Observation: 
 Udal Thathukkal Saaram&Chenneerwasaffected in all cases. Oon and Kozhuppu 
was affected in 5% (2 cases) each. Sukilam was affected in 5% (2 cases). 
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MUKKUTRANGAL: 
VATHAM: 
S.NO VATHAM NO.OF CASES PERCENTAGE 
1 Pranan 0 0% 
2 Abanan 27 67.50% 
3 Udhanan 5 
12.5% 
4 Viyanan 34 85% 
5 Samanan 34 87.50% 
6 Nagan 0 0 
7 Koorman 4 10% 
8 Kirukaran 4 10% 
9 Devathathan 24 60% 
10 Dhananjeyan 0 0 
 
 
Observation: 
Viyaanan (pain present in the both upper and lower limbs, burning sensation 
presentin the both soles) was affected in 85% (34cases). Udhanan (tiredness, drowsiness) 
was affected in 12.5% (5 cases) and Abaanan (polyuria, constipation, nocturia)was affected 
in 67.5% (27 cases), Samaanan was affected 90%(36cases) and Kirukaran (polyphagia)was 
affected in 10% (4cases), koorman was affected in (10% (4cases), and Devathaththan 
(tiredness,anxiety) was affected in 60% (24 cases). 
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PITHAM 
S.NO PITHAM NO.OF CASES PERCENTAGE 
1 Anarpitham 4 10% 
2 Ranjagapitham 0 0% 
3 Saathagapitham 34 85% 
4 Prasagam 2 5% 
5 Alosagam 0 0% 
 
 
Observation: 
Among 40 cases Saathaga pittham (general tiredness) was affected in 85% (34 
cases). Anal pittham (Increased appetite) was affected in 10% (4 cases), Pirasaga pittham 
(Dryness of skin) was affected in 5% (2 cases),Aalosaga pitham (dullness of vision) was 
affected in 10% (4 cases). 
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KABAM: 
 
S.NO KABAM NO.OF CASES PERCENTAGE 
1 Avalambagam 34 85% 
2 Kilethagam 5 12.5 % 
3 Pothagam 0 0 
4 Tharbagam 0 0 
5 Santhigam 34 85% 
 
 
 
Observation: 
Among 40 patients Avalambagam was affected in 85% (34cases), 
Kilethagam(increased appetite) was affected in 12.5% (5cases), Santhigam(Joint pain) was 
affected in 85% (34cases). 
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ENVAGAI THAERVUGAL:  
S.NO Envagai Thervu NO.OFCASES PERCENTAGE 
1 Naa 4 10% 
2 Niram 2 50% 
3 Mozhi 0 0 
4 Vizhi 4 10% 
5 Malam 0 0 
6 Moothiram   
Slowly spread 27 67.5% 
Fastly spread 22 55% 
7 Naadi   
Vatha pitham 16 40% 
Pitha vatham 12 30% 
Pitha kabham 6 15% 
 Kabha pitham 4 10% 
 Vatha kabham 2 5% 
8 Sparisam 0 0 
 
 
Observation: 
In Ennvagai thervugal oil in urine (Neikuri) was slowly spread in 67.5% (27cases). 
fastly spread in 55% (22cases). Vizhi (Eye) affected (burning sensation of both 
eyes/cataract/diminished vision) in 10% (4 cases) and Naa was affected in 10% (4 cases). 
Naadi was vaatha piththam in 40%(16) cases, Piththa vaatham in 30% (12) of cases and 
Piththa kapham in 15% (6) of cases and vatha kapham in 5%(2) of cases, Kapha pitham 
was noted in 10% (4) cases. 
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CLINICAL FEATURES: 
 
CLINICAL 
FEATURES 
NO.OF CASES IMPROVEMENT% 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Polyuria 25 7 62.5% 17.5% 
Polyphagia 4 1 10% 2.5% 
Polydipsia 5 2 12.5% 5% 
Nocturia 27 9 67.55% 22.5% 
General tiredness 34 15 85% 37.5% 
Burning foot 4 1 10% 2.5% 
 
 
Observation: 
62.50% (25cases) had complains of polyuria and 10 % (4 cases) had complaints of 
Polydipsia 12.5 % (5 cases) had complaints of polyphagia, 67.5 % (27 cases) had 
complaints of nocturia, ,10%(4cases) had complaints of pain and burning sensation in the 
both sole, and 85% (34 cases) had complaints of Tiredness. 
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CHRONICITY OF ILLNESS: 
 
S.NO CHRONICITY OF ILLNESS NO.OF CASES PERCENTAGE 
1 0-1 years 18 45% 
2 1-3 years 15 37.5% 
3 3-5 years 5 12.5% 
4 5-10 years 2 5% 
 
 
 
 
Observation: 
45% (18 patients) had the history of this disease up to 0-1 years only. 37.5% (15 
patients) suffered for1-3 years and 12.5 % (5patients) for3-5 years. And 5% (2 patients) for 
5-10 years. 
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Statistical significance of biochemical values in Maruthampattai Kudineer treated 
patients 
 FASTING BLOOD SUGAR 
 
 No .of 
patients 
Mean ±SD P value T value 
Before treatment 40 142.1± 33.08 0.34 2.193 
After treatment 40 134±26.49 
  
POSTPRANDIAL BLOOD SUGAR 
 
 No .of 
patients 
Mean ±SD P value T value 
Before treatment 40 233.95± 50.79 0.0007 3.68 
After treatment 40 208.77 ±53.60 
 
GLYCOSYLATED HAEMOGLOBIN 
 
 No .of 
patients 
Mean ±SD P value T value 
Before treatment 40 7.25 ± 0.91 0.0025 3.225 
After treatment 40 6.91 ±0.86 
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GROUP NO.OF 
PATIENTS 
GOOD 
CONTROL 
POOR 
CONTROL 
Group 1 (Trial medicine 
with yogam) 
 
20 15 5 
Group 2 (Only trial 
medicine) 
 
20 9 11 
 
Observation: 
                    The outcome of the study showed encouraging results.Hba1c which is a reliable 
biomarker for the diagnosis and prognosis of diabetes was found to be under good control in 
15 patients and poor control in 5 patient in group 1 patients treated with trial medicine and 
yogam.It was found to in good control in 9 patients and poor control in 11 patients in group 
2 treated with the trial medicine alone.  
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DISCUSSION 
Diabetes is a metabolic disorder with an alarming rise in its incidence.It affects the 
quality of life of a person. The goal of diabetes management is to prevent or treat the many 
complications that can result from the disease itself and from its treatment. 
 
The trial drug was prepared in Gunapadam lab of National Institute of Siddha after 
the authentication of the raw drugs by Assistant professor of medicinal botany NIS Chennai.  
 
The Bio chemical analysis was done at the biochemistry lab of NIS and the results 
were documented. The Bio-chemical analysis of Kukkil chooranam had shown the presence 
of Sulphate, Phosphate, Carbonate, Calcium,Alkaloids, Tannic acid, 
Oxyquinalone,epinephrine and pyro catechol.Their presence indicates the antioxidant, 
antimicrobial, anti-septic, properties of the drug.  
 
The physico chemical analysis demonstrated the following results with pH (10 % 
w/v aq. solution4.96, Loss on drying at 105°C11.58 %,Total ash value 16.74 %, Acid-
insoluble ash value 0.98 %,Water-soluble extractive24.29 %,Alcohol soluble 
extractive18.96 %. 
 
The α –amylase anti diabetic activity revealed high performance activity compared 
to the standard drug acarbose. The trial drug exhibited comparable antioxidant property 
done using ABTS assay. 
 
 The Acute and 90 days repeated oral toxicity studies did not show any toxic effects 
in the animals. 
 
Clinical study: 
 For this study, 40 patients were selected and patients were treated in the OP 
department of Sirappu Maruthuvam, in Ayothidoss Pandithar Hospital of National Institute 
of Siddha, Tambaram Sanatorium, Chennai – 600 047. 
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The trial drug maruthampattai kudineer was given for 90 days. OPD patients were 
requested to visit the hospital once in 7 days. In each and every visit clinical assessment and 
prognosis were recorded.  Group II patients were taught Yogasanam on each visit. 
Laboratory investigations were done for all the cases before and after treatment. Based on 
various criteria, the data were collected and tabulated. The criteria were family history, sex 
predominance, age distribution, occupation, dietary habits, chronicity of illness and clinical 
features assessment of the improvement in the prognosis of the disease with the trial drug. 
40 patients of both genders were recruited for this study. Among the 40 cases, 26 (65%) 
were males and 14 (35%) were females. Generally diabetes occurs with high incidence in 
male compared to female. More number of male cases reported in this study. 
 
Among 40 patients admitted in the trial 25% (10cases) were in the age group  of 35-
45 , 37.5% (15 cases) were in the age group 45-55 and 37.5% (15 cases)  were in the age 
group 55-65.   
 
             Out of 40 cases 90% of patients (36 cases) were Hindu. 
 
 Out of 40 cases 7.5% of patients (3) were Drivers, 5% (2) patients were Carpenter, 
2.5% (1) case was shop keeper, 50% of patients (20) were manual workers, 27.5% of 
patients (11) were house wives, 2.5% (1) case was nurse, 2.5% (1) case was business man 
and 2.5% (1) case was security. 
 
Out of 40 Patients 27 cases (67.5%) had positive family history of Type 2 diabetes 
reveals genetic predisposition of the disease. 
 
 Out of 40 cases 22.5% of patients (9 cases) were smokers, 27.5% (11) patients were 
alcoholic, and 50 % (20) cases were Non-smokers& Non Alcoholic. Irrespective of personal 
habits the disease affects all groups such as smokers, alcoholic, non-smokers & non-
alcoholic 
 
The majority of patients in this study were Non vegetarian 36 (90%) remaining 4 
(10%) patients were vegetarian. 
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In this present study, considerable numbers of patients reported from Neithal thinai 
(36 patients),Marutham  thinai (4 patients).  
 
All the patients included for the study were from pitha kalam (34-66 years) reveals 
the incidence of diabetes is commom among middle aged and old aged people. 
 
Out of 40 cases all patients had raso gunam. 
 
Among 40 cases most of them (21cases) were included in the trial in 
pinpanikalam,(52.5%) . 
 
In Udal Thathukkal Saaram & Chenneer wasaffected in all cases. Oon and 
Kozhuppu was affected in 5% (2) of cases each. Sukilam was affected in 5% (2) of cases. 
 
Viyaanan (pain present in the both upper and lower limbs, burning sensation 
presentin the both soles) was affected in 85% cases (34). Udhanan (tiredness, drowsiness) 
was affected in 12.5% (5 cases) and Abaanan (polyuria, constipation, nocturia)was affected 
in 67.5% (27 cases), Samaanan was affected 90%(36cases) and Kirukaran (polyphagia)was 
affected in 10% (4cases), koorman was affected in (10% (4cases), and and Devathaththan 
(tiredness,anxiety) was affected in 60% cases(24 cases). 
 
Among 40 cases Saathaga pittham (general tiredness) was affected in 85% (34) 
cases. Anal pittham (Increased appetite) was affected in 10% of cases (4 cases), Pirasaga 
pittham (Dryness of skin) was affected in 5% cases (2cases), Aalosaga pitham (dullness of 
vision) was affected in 10% of cases (4). 
 
Among 40 patients Avalambagam was affected in 85% (34cases), 
kilethagam(increased appetite) was affected in 12.5% (5cases), Santhigam(Joint pain) was 
affected in 37.5 %(15). 
 
45% (18) patients had the history of this disease up to 0-1 years only. 37.5% (15) of 
patients suffered for1-3 years and 12.5 % (5) patients for3-5 years, and 5% (2) patients for 
5-10 years. 
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In Ennvagai thervugal oil in urine (Neikuri) was slowly spread in 67.5% (27cases). 
fastly spread in 55% (22) cases. Vizhi (Eye) affected (burning sensation of both 
eyes/cataract/diminished vision) in 10% (4 cases) and Naa was affected in 10% (4 cases). 
Naadi was vaatha piththam in 40%(16) cases, Piththa vaatham in 30% (12) of cases and 
Piththa kapham in 15% (6) of cases and vatha kapham in 5%(2) of cases, Kapha pitham was 
noted in 10% (4) cases. 
 
62.50% (25cases) patients had complains of polyuria and 10 % (4 cases) complaints 
of Polydipsia 12.5 % (5 cases) complaints of polyphagia, 67.5 % (27 cases) complaints of 
nocturia, ,10%(4cases) complaints of pain and burning sensation in the both sole, and  
85% (34 cases) complaints of Tiredness.the statistical significance of the biochemical 
parameters in maruthampattai kudineer treated subjects were expressed as Mean ± Standard 
Error of Mean . A probability value of <0.05 was considered to be statistically significant. 
 
The mean± standard error of mean of fasting blood sugar before and after treatment 
were 142.1± 33.08 and 134.82± 26.49 respectively which is statistically significant (t = 
2.1938, p  value 0.0343) 
 
The mean± standard error of mean of postprandial blood sugar before and after 
treatment were 233.95± 50.79 and 208.77± 53.60 respectively which is statistically 
significant (t = 3.6817, p  value 0.0007) 
 
The mean± standard error of mean of HBA1C before and after treatment were 7.25± 
0.918 and 6.91± 0.869 respectively which is statistically significant (t = 3.2257, p value 
0.0025) 
 
The outcome of the study showed encouraging results.Hba1c which is a reliable 
biomarker for the diagnosis and prognosis of diabetes was found to be under good control in 
15 patients and poor control in 5 patient in group 1 patients treated with trial medicine and 
yogam.It was found to in good control in 9 patients and poor control in 11 patients in group 
2 treated with the trial medicine alone. 
 
135 
 
In this study, no adverse events were observed during the course of the treatment. At 
the end of the study, all the patients were advised to attend out-patient department of 
Sirappu Maruthuvam of NIS for further follow-up. 
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SUMMARY 
This study protocol has been approved by Institutional Ethical Committee ofNIS 
(IEC Approval number: NIS/IEC/2016 11-09/14.10.2016) 
The raw drugs of Maruthampattai kudineer were identified and authentication 
certificate was obtained.  
The Biochemical analysis of the trial drug was done in the Biochemistry lab of 
National Institute of Siddha. 
The physicochemical analysis of the prepared drug revealed that it was in the 
standard quality.  
The toxicity study (acute and repeated-dose 90days toxicity) of the trial drug was 
done in NIS Chennai. The study shows that Maruthampattai kudineer did not produce any 
toxic effect at dose of 2000 mg/kg. So No-Observed-Adverse-Effect-Level (NOAEL) of 
maruthampattai kudineer is 2000 mg/kg.  
 The disease Madhumegam was taken for the clinical study with Maruthampattai 
kudineer and 40 cases were selected based on the approved protocol. Animal studies were 
done after obtaining approval from the Animal Ethical Committee (IAEC). Hence the study 
was safely executed on patients and there was no adverse drug reactions noted during the 
study period.All the patients were treated with Trial drug Maruthampattai kudineer before 
food twice a day for 90 days .Among the 40 patients 20 patients were adviced to do specific 
yoga module. 
Haematological, Biochemical and Urine examination were done before and after 
treatment. Blood sugar (F) and (PP), HBA1c were done before and after treatment. 
Statistical Analysisweredone after treatment. 
Because of the hopeful results clinically, the study may be undertaken with the 
samedrug for a prolonged period in more number of cases and it may throw new lights in 
the managemet of Madhumegam. 
 
 
     
 
137 
 
   CONCLUSION 
 
 The poly herbal formulation Maruthampattai kudineer exhibited no toxicity on long 
term administration. 
 The present clinical study confirms the efficacy and safety of the trial drug 
“Maruthampattai kudineer” which is Siddha poly herbal formulation. It was found to be 
good resulting on madhumegam patients in maintaing their fasting, postprandial and 
HBA1C levelsThe clinical symptoms such as polyuria, polydipsia, nocturia, and burning 
foot reduced considerably. 
 
 Though there are several classes of modern drugs available in the management 
diabetes they have their own characteristic profile of side effects.this present study 
highlights the point that the use of only a polyherbal medicine maruthampattai kudineer in 
management of diabetes was found to be efficacious. The intervention of yoga along with 
trial medicine produced better results. The present study enumerates the need to sensitize 
the community to adopt siddha medicines and yogam as a measure to manage diabetes. 
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NATIONAL INSTITUTE OF SIDDHA, 
AYOTHIDASS PANDITHAR HOSPITAL, 
CHENNAI 47. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
“PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN THE 
MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES) 
  
FORM-l (SCREENING & SELECTION PROFORMA)  
 
1. SI NO: _______  
2. OP/IP NO: _________  
3. NAME:__________ 
4. RELIGION: H/C/M/O  
5. AGE: _____  
6. GENDER: ___________ 
 
INCLUSION CRITERIA  
 Age : 30-65 years        YES/NO 
 Gender:  Male/ Female  
With symptoms of 
 Polyuria,Polydipsia,Nocturia,Polyphagia     YES/NO 
 Blood glucose level: 
 Fasting plasma blood glucose level-≤ 150 mg/dl   YES/NO 
 Two Hours postprandial plasma blood glucose level- ≤250 mg/dl YES/NO 
 Glycosylated haemoglobin (HbA1c)  ≤ 8%    YES/NO
  
 Non Insulin Dependent Diabetes Mellitus     YES/NO 
 
EXCLUSION CRITERIA 
 Fasting plasma blood glucose level- >151 mg/dl    YES/NO 
 2 Hours postprandial plasma blood glucose level- >251 mg/dl  YES/NO 
 Glycosylated haemoglobin (HbA1c)- > 8.1%    YES/NO 
 Patient with diabetic complications diabetic foot, retinopathy etc.,  YES/NO 
 Insulin Dependent Diabetes Mellitus      YES/NO 
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 Any other serious Systemic Diseases      YES/NO 
 Pregnancy and lactation       YES/NO 
 
ADMITED TO TRAIL Yes /No If Yes, Serial NO: ______________  
DATE: STATION:  
 
SIGNATURE OF THE INVESTIGATOR 
 SIGNATURE OF THE LECTURER  
SIGNATURE OF THE HOD 
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NATIONAL INSTITUTE OF SIDDHA, 
AYOTHIDASS PANDITHAR HOSPITAL, 
CHENNAI 47. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN THE 
MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES) 
 
FORM II-CASE RECORD FORM 
 
STUDY  NO:   OP / IP NO: 
 
NAME: AGE / GENDER: 
 
ADDRESS: CONTACT NO : 
 
 RELIGION :  H / C / M / O. 
 
OCCUPATION: 
 
INCOME: 
MARITAL STATUS :       1. Married 2. Unmarried 
 
DATE OF INTIAL ASSESSMENT: 
 
 
COMPLAINTS & DURATION:  
 
 
 
 
PERSONAL HISTORY: 
 
 
PERSONAL HABITS YES NO 
IF YES SPECIFY 
DURATION 
AMOUNT/Quantity 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic  Drug Addiction     
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HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
FAMILY HISTORY: 
 
Whether this problem runs in family? 
 
1. Yes            2. No    
If yes, mention the relationship of affected person(s) 1._________________ 
 
2._________________ 
 
DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
MENSTURAL AND OBSTETRIC HISTORY  
 
FORM II B 
GENERAL EXAMINATION 
1. Body weight [Kg]    :                      
2. Height [cms]                       :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mm/Hg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.  :   
Yes            No   
8. Pallor   :   
9. Jaundice   :   
10. Clubbing   : 
11. Cyanosis   : 
12. Pedal Oedema   : 
13. Lymphadenopathy      :  
14. Jugular venous pulsation  :   
SYSTEMIC EXAMINATION 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
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SIDDHA SYSTEM OF EXAMINATION: 
1. Vathaudal 
2. Pithaudal 
3. Kabaudal 
4. Thonthaudal 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji(Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
3. KAALAM: 
1. Kaarkaalam (Aavani-Purattasi) 
2. Koothirkaalam (Ippasi-Kaarthigai) 
3. Munpanikaalam (Maargazhi-Thai) 
4. Pinpanikaalam (Maasi-Panguni) 
5. Ilavenilkaalam (Chithirai-Vaigasi) 
6. Muthuvenilkaalam (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
 
5. PORIPULANGAL (SENSORY ORGANS):   
 
 
 
 
 
 
 
 
 
 
 
 
 Before treatment After treatment 
Mei (Skin) Normal  / Affected Normal  / Affected 
Vai (Tongue) Normal  / Affected Normal  / Affected 
Kann (Eye) Normal  / Affected Normal  / Affected 
Mooku (Nose) Normal  / Affected Normal  / Affected 
Sevi (Ear) Normal  / Affected Normal  / Affected 
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6.KANMENDRIYAM (MOTOR ORGANS) : 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. KOSANGAL (SHEATH):   
  
 
 
 
 
 
 
  
 
 
 
 
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 
 
 Before treatment After treatment 
Saaram Normal  /Affected Normal  /Affected 
Senneer Normal  /Affected Normal  /Affected 
Oon Normal  /Affected Normal  /Affected 
Kozhuppu Normal  /Affected Normal  /Affected 
Enbu Normal  /Affected Normal  /Affected 
Moolai Normal  /Affected Normal  /Affected 
Sukkilam / Suronitham Normal  /Affected Normal  /Affected 
 
 
 Before treatment After treatment 
Kai (Upper limb) Normal  /Affected Normal  /Affected 
Kaal(Lower limb) Normal  /Affected Normal  /Affected 
Vai(Oral cavity) Normal  /Affected Normal  /Affected 
Eruvai(Anal region) Normal  /Affected Normal  /Affected 
Karuvai (Uro-Genital 
region) 
Normal  /Affected Normal  /Affected 
 Before treatment After treatment 
Annamayakosam Normal  /Affected Normal  /Affected 
Pranamayakosam Normal  /Affected Normal  /Affected 
Manomayakosam Normal  /Affected Normal  /Affected 
Vignanamayakosam Normal  /Affected Normal  /Affected 
Ananthamayakosam Normal  /Affected Normal  /Affected 
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9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
A) VALI 
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th
 
day 
Praanan               
Abaanan               
Samaanan               
Udhaanan               
Viyaanan               
Naagan               
Koorman               
Kirukaran               
Devathathan               
Dhananjeyan         
      
 
 
 
 
B) AZHAL 
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Anarpitham               
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Prasagam               
Aalosagam               
Sathagam               
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C) IYYAM 
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10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
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II SPARISAM: [PALPATION] 
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III.NAA: [TONGUE] 
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IV. NIRAM: [COMPLEXION]  
 
 1. Vadham   
 
 2. Pitham 
 
 3. Kabam 
 
V. MOZHI: [VOICE] 
 
1. High Pitched 
 
      2. Low Pitched 
 
      3. Medium Pitched 
 
 
VI.VIZHI: [EYES] 
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VII. MALAM: [BOWEL HABITS / STOOLS] 
 
 
 
 Before treatment After treatment 
Niram   
Irugal   
Ilagal   
Others   
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VIII. MOOTHIRAM [URINE EXAMINATION] 
   
NEERKKURI: 
 
 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
 
 
NEIKKURI:  
 
Neikkuri Before treatment After treatment 
Aravananeedathu/ 
Snake like pattern 
 
  
Azhipolparaviyathu 
Annular/Ringedpattern 
 
 
 
paravparaparavoiyadu 
  
Muththothuninrathu 
Pearlbeadepattern 
  
Other patterns   
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN THE 
MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES) 
 
Principal Investigator: Dr. B.Vinubharathi 
 
FORM –VI- DRUG COMPLIANCE FORM 
 
SERIAL NO:     
 
NAME:  
 
DRUG NAME:  
 
On 1
st    
 day-Date: Drugs issued: (Gms) Drugs returned:    (Gms) 
On 8
th
   day-Date:  Drugs issued: (Gms) Drugs returned:    (Gms) 
On 15
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 22
th
 day-Date:           Drugs issued: (Gms) Drugs returned:    (Gms) 
On 29
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 36
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 43
th
 day-Date:            Drugs issued: (Gms) Drugs returned:    (Gms) 
On 49
th
   day-Date:  Drugs issued: (Gms) Drugs returned:    (Gms) 
On 56
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 63
rd 
 day-Date: Drugs issued: (Gms) Drugs returned:    (Gms) 
On 70
th
 day-Date:  Drugs issued: (Gms) Drugs returned:    (Gms) 
On 77
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
On 84
th
 day-Date:           Drugs issued: (Gms) Drugs returned:    (Gms) 
On 90
th
 day-Date:             Drugs issued: (Gms) Drugs returned:    (Gms) 
 
   Day    Date          Morning   Evening   Day    Date    Morning   Evening 
Day 1    Day46    
Day2    Day47    
Day3    Day48    
Day4    Day49    
Day5    Day50    
Day6    Day51    
Day7    Day52    
Day8    Day53    
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Date:  
         
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
Day9    Day54    
Day10    Day55    
Day11    Day56    
Day12    Day57    
Day13    Day58    
Day14    Day59    
Day15    Day60    
Day16    Day61    
Day17    Day62    
Day18    Day63    
Day19    Day64    
Day20    Day65    
Day21    Day66    
Day22    Day67    
Day23    Day68    
Day24    Day 69    
Day25    Day70    
Day26    Day71    
Day27    Day72    
Day28    Day73    
Day29    Day74    
Day30    Day 75    
Day31    Day 76    
Day32    Day77    
Day33    Day78    
Day34    Day79    
Day35    Day80    
Day36    Day81    
Day37    Day82    
Day38    Day83    
Day39    Day84    
Day40    Day85    
Day41    Day86    
Day42    Day87    
Day43    Day88    
Day44    Day89    
Day45    Day90    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, 
       CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN THE 
MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES) 
 
FORM V– PATIENT INFORMATION SHEET 
Name of Principal Investigator: Dr.B.Vinubharathi 
Name of the institute: National Institute of Siddha, 
                                      Tambaram Sanatorium, 
                                      Chennai-47. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
I, Dr.B.Vinubharathi,studying M.D (Siddha) at National Institute of Siddha, Tambaram 
Sanatorium is  going to do a trial on “Madhumegam” (Diabetes).Diabetes mellitus is a 
condition where the body fails to utilize the ingested glucose properly. It is a metabolic disorder and 
caused by lack of the insulin or insufficiency of insulin actions. 
In this regard, I am in a need to ask you few questions. I will maintain confidentiality of 
your comments and data obtained. There will be no risk of disclosing your identity and no 
physical, psychological or professional risk is involved by taking part in this study. Taking 
part in this study is voluntary. No compensation will be paid to you for taking   part in this 
study. 
           You can choose not to take part. You can choose not to answer a specific question. 
There is no specific benefit for you if you take part in the study. However, taking part in the 
study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
“MARUTHAM PATTAI KUDINEER” (Internal medicine) 60ml bidand „YOGAM” 
(External therapy) for 90 days.  
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The information I am collecting in this study will remain between you and the 
principal investigator (I). I will ask you few questions through a questionnaire. I will not 
write your name on this form. Your name won‟t be mentioned in the lab investigation form 
instead a code will be used. 
The questionnaire will take approximately 20 minutes of your time. 
If you want to know more about this study before taking part, you can contact 
Dr.B.Vinubharathi, PG Scholar, principal investigator of this study,National Institute of 
Siddha, Chennai-47. You can also contact the Member-secretary of Ethics committee, 
National Institute Siddha, Chennai 600047, Tel.No: 91-44-22380789, for rights and 
participation in the study. 
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¾¸Åø ÀÊÅõ 
    §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
       «§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
        ¦ºý¨É-47 
 
ÁÐ§Á¸õ ±ýÛõ §¿¡öì¸¡ÉÁÕ¾õÀð¨¼ÌÊ¿£÷ ÝÃ½õ(¯û ÁÕóÐ) 
ÁüÚõ §Â¡¸õ (ÒÈ ÁÕòÐÅõ) º¢ò¾ ÁÕóÐ¸Ç¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
Ó¾ý¨Á ¬öÅ¡Ç÷ ¦ÀÂ÷:  ÁÕòÐÅ÷.À¡.Å¢ÛÀ¡Ã¾¢ 
 
 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷:  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
     ¾¡õÀÃõ, º¡Éð§¼¡¡Ã¢Âõ, 
     ¦ºý¨É - 47. 
 
 
§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒÀÂ¢ýÚÅÕõ 
¿¡ý(ÁÕòÐÅ÷-À¡.Å¢ÛÀ¡Ã¾¢), ÁÐ§Á¸õ §¿¡Â¢øÁÕòÐÅ ¬Ã¡öîº¢Â¢ø 
®ÎÀðÎû§Çý. 
 
ÁÐ§Á¸õ(Å¨¸ 2 ¼Â¡À¢ÊŠ ¦ÁøÄ¢¼Š) ±ýÛõ ÅÇ÷º¢¨¾ 
Á¡üÈ§¿¡Â¡ÉÐ ¸¨½Âõ ±ýÛõ ¿¡ÇÁ¢øÄ¡ ÍÃôÀ¢Â¢ýþýÍÄ¢ý 
†¡÷§Á¡ýÀÂýÀ¡ðÎ ¾¨¼Â¢ý ¸¡Ã½Á¡¸§Å¡,þýÍÄ¢ýÌ¨ÈÀ¡ðÊý 
¸¡Ã½Á¡¸§Å¡ «øÄÐþÃñÊý ¸¡Ã½Á¡¸§Å¡ ÌÕ¾¢Â¢ø º÷ì¸¨ÃÂ¢ý 
«Ç× «¾¢¸ôÀÎòÐõ §¿¡Â¡Ìõ. þó§¿¡ö «Êì¸Ê º¢Ú¿£Ã¢Æ¢¾ø, «¾¢¸ Àº¢, 
«¾¢¸ ¾¡¸õ,¯¼ø §º¡÷×,«º¾¢,¸¡ø ±Ã¢îºø §À¡ýÈ ÌÈ¢Ì½í¸¨Ç 
§¾¡üÚÅ¢ìÌõ.  
 
þó¾ ¬Ã¡öîº¢ ºõÁó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç §¸ð¸×õ,§¾ÅÂ¡É 
¬öÅ¸ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ÀÃ¢§º¡¾¨ÉìÌ ¯ðÀÎò¾×õ ¯û§Çý, 
«Ð ºõÁó¾Á¡É ¾í¸ÇÐ «¨ÉòÐÅ¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡ö ¨Åì¸ÀÎõ ±É 
¯Ú¾¢ «Ç¢ì¸¢§Èý. 
 
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ ¦¾¡¨¸Ôõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð. 
 
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ±üÀÎõ Àðºò¾¢ø §¾º¢Â 
º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ. 
 
þó¾ ¬Ã¡öîº¢ìÌ ¾í¸Ç¢ý Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø 
ÁÕ¾õÀð¨¼ÌÊ¿£÷ ÝÃ½õ ¯ûÁÕó¾¡¸ 60Á¢.Ä¢ þÕ§Å¨Ç (¸¡¨Ä, 
Á¡¨Ä) ¯½×ìÌ À¢ý ¿¡ð¸û ¯ð¦¸¡ûÇ §ÅñÎõ,ÌÈ¢ôÀ¢ð¼ §Â¡¸ 
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Ó¨È¸¨Ç ¾¢Éõ ´Õ Ó¨È(30-45 ¿¢Á¢¼õ) ÀÂ¢üº¢ ¦ºöÂ ÅÄ¢ÔÚò¾ôÀÎõ. 
 
þó¾ ¬Ã¡öîº¢Â¢ø §¿¡Â¢ÉÃ¡¸ §º÷ó¾ À¢ÈÌ 
¯í¸ÙìÌÅ¢ÕôÀõþø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ Å¢Ä¸¢ 
¦¸¡ûÇÄ¡õ. 
þó¾ ¬Ã¡öîº¢Â¢ø ºõÁó¾Á¡¸ ÁüÈÅ¢ÀÃí¸ÙìÌõ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ 
Ó¾ý¨Á¬öÅ¡ÇÃ¡É ÁÕòÐÅ÷ À¡.Å¢ÛÀ¡Ã¾¢ Àð¼ §ÁüÀÊôÀ¡Ç¡÷ 
º¢ÈôÒÁÕòÐÅ Ð¨È) «Ï¸×õ.¨¸§Àº¢ ±ñ: 
 
§ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ IEC º¡ýÚ ¦ÀÈÀðÎûÇÐ. 
 
§ÁÖõ ¯½× Ó¨ÈÂ¢øÁÕòÐÅÃ¡øÜÈôÀÎõ Àò¾¢Âõ ¸¡ìÌÁ¡Ú 
«È¢×Úò¾ôÀÎ¸¢ÈÐ. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, 
CHENNAI – 600 047. 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
“PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN THE 
MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES)” 
 
Principal Investigator: Dr. B.Vinubharathi 
 
FORM-V – CONSENT FORM 
 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to my 
satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand that I 
have the   right to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm individual has given consent 
freely.”                                                   
 
Date: 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)    
     
 
 
 
 
 
 
 
 
Left thumb Impression of the Participant 
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´ôÒ¾ø ÀÊÅõ 
¬öÅ¡ÇÃ¡ø-º¡ýÈÇ¢ì¸ôÀð¼Ð 
      
    §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, 
    «§Â¡ò¾¢¾¡Š ÀñÊ¾÷ ÁÕòÐÅÁ¨É, 
    ¦ºý¨É-47. 
 
ÁÐ§Á¸õ ±ýÛõ §¿¡öì¸¡ÉÁÕ¾õÀð¨¼ÌÊ¿£÷ ÝÃ½õ(¯û ÁÕóÐ) 
ÁüÚõ §Â¡¸õ º¢ò¾ ÁÕóÐ¸Ç¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ 
¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
 
   ´ôÒ¾ø ÀÊÅõ-¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀðÎûÇÐ 
 
¿¡ý þó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐÅ¢ÀÃí¸¨ÇÔõ §¿¡ÂÇ¢ìÌôÒÃ¢Ôõ 
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
§¾¾¢:          
 ¨¸¦Â¡ôÀõ: 
þ¼õ:          ¦ÀÂ÷:
    
    §¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø  
 
±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ,ÁÕó¾¢ý ¾ý¨Á 
ÁüÚõÁÕòÐÅ ÅÆ¢Ó¨È ÀüÈ¢Ôõ,¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ì 
¸ñ¸¡½¢ì¸×õ, «¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõÁÕòÐÅ ¬ö×ìÜ¼ 
ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢ «Ç¢ìÌõ Å¨¸Â¢øÁÕòÐÅÃ¡øÅ¢Çì¸¢ì 
ÜÈôÀð¼Ð. 
¿¡ý þó¾ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨ÉÅ¢ÎÅ¢òÐì ¦¸¡ûÙõ ¯Ã¢¨Áò 
¦¾Ã¢ó¾¢Õì¸¢§Èý. ¿¡ý ±ýÛ¨¼Â Í¸ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Áì 
¦¸¡ñÎÁÐ§Á¸õ ±ýÛ §¿¡öì¸¡ÉÁÕ¾õÀð¨¼ ÝÃ½õ(¯û ÁÕóÐ) 
ÁüÚõ §Â¡¸õ ÁÕòÐÅò¾¢ý ÀÃ¢¸Ã¢ôÒ ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ 
¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
§¾¾¢:        ¨¸¦Â¡ôÀõ: 
þ¼õ:        ¦ÀÂ÷: 
        º¡ðº¢¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
        ¦ÀÂ÷: 
 
¯È×Ó¨È: 
Å¢Ã¢×¨ÃÂ¡Ç÷ ¨¸¦Â¡ôÀõ:                       Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ:  
168 
 
NATIONAL INSTITUTE OF SIDDHA, 
AYOTHIDASS PANDITHAR HOSPITAL CHENNAI 47, 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF 
MARUTHAMPATTAI KUDINEER AND YOGAM THERAPY IN 
THE MANAGEMENT OF MADHUMEGAM (TYPE II DIABETES) 
  
FORM VII- WITHDRAWAL FORM 
 
IEC NO:  
 
NAME: _______________________________  
 
OPD/ IPD NUMBER: _____________ 
 
 AGE: _________ SERIAL NO: _____________________ 
 
DATE OF TRIAL COMMENCEMENT: 
 
DATE OF WITHDRAWAL FROM TRIAL: 
 
REASONS FOR WITHDRAWAL:  
 
Long absence at reporting:    Yes/ No  
  
Irregular treatment:      Yes/ No  
 
Shift of locality:     Yes/No  
 
Increase in severity of symptoms:    Yes/No  
 
Development of severe adverse drug reactions: Yes/No  
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Form VII B – ADVERSE REACTION FORM/ PHARMACOVIGILANCE FORM  
 
 
1. S.l. No: 2. OP/ IP No  : 3. Name: 
4. Age: 5. Gender: 6. Date of Enrollment: 
7. Date of completion: 8. Informant: 9. Reliability: 
 
Name       : 
Age       : 
Gender    : 
OPD/ IPD No    : 
Registration No    : 
Date of trial commencement  : 
Date of withdrawal from trial   : 
Description of adverse reaction  : 
 
Date:        Signature of Investigator 
           
          Signature of Guide                   
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§º÷ì¸ ÜÊÂ ¯½×¸û: 
¸¡ö¸û: 
ÓÕí¨¸À¢ïÍ, 
«Å¨ÃÀ¢ïÍ, 
À¢Ãñ¨¼, 
¸¡Ãð, 
À£ðåð. 
¸£¨Ã¸û: 
¸Ã¢º¡¨Ä, 
¦À¡ýÉ¡í¸ñ½¢, 
Á½ò¾ì¸¡Ç¢,              
ÓÕí¨¸¸£¨Ã, 
Àº¨Ä¸£¨ Ã, 
º¢Ú¸£¨ Ã,                 
¸È¢§ÅôÀ¢¨Ä,  
      ¦¸¡ò¾ÁøÄ¢. 
Ò¾¢É¡. 
ÀÆí¸û: 
Á¡Ð¨Ç, 
¬ôÀ¢û, 
Å¡¨Æ, 
§ÀÃ£î¨º, 
«ò¾¢,               
¾¢Ã¡ð¨º, 
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¦¸¡öÂ¡                
¿¡Åø, 
ºô§À¡ð¼¡, 
¯Ä÷ ¾¢Ã¡ð¨º. 
¾¡É¢Âí¸û 
Ó¨Ç ¸ðÊÂ ÀÂ¢÷ Å¨¸¸û,  
§º¡Â¡À£ýŠ, 
 ¦Åó¾Âõ. 
 
«¨ºÅõ: 
¦ÅûÇ¡ðÎ¸È¢ ®Ãø, 
±ÖõÒÁˆ¨ƒ, 
ÁüÈ¨Å: 
À¨É ¦ÅøÄõ 
À¡ø 
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û:  
§¸¡Æ¢ì¸È¢, Á£ý, ¿ñÎ, ¸ÕÅ¡Î, 
§Å÷ì¸¼¨Ä, 
±ûÙ, 
ÀôÀ¡Ç¢, 
«ýÉ¡º¢, 
¿ø¦Äñ¦½ö, 
ÒÇ¢ôÒ ¦À¡Õû¸û, 
±ÖÁ¢î¨º, 
¾ì¸¡Ç¢, 
°Ú¸¡ö, 
¦Àñ§À¡¸õ, Ò¨¸Â¢¨Ä , 
¦ÅüÈ¢¨Ä,À¡ìÌ. 
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